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ABBY GOODSON WENZEL. Prevalence and potential reproductive health impacts of 
phthalates and phthalate alternatives in pregnant women in Charleston, South Carolina. 
(Under the direction of JOHN KUCKLICK). 
Phthalates are plasticizers commonly detected in humans due to widespread 
exposure from PVC plastics, food packaging, and personal care products. Several 
phthalates are known antiandrogens, raising concern for prenatal exposures during 
critical windows of fetal development. The goal of the research presented here is to 1) 
Determine if certain demographics have greater or lesser phthalate concentrations, 2) 
Evaluate associations between prenatal phthalate exposure and AGD, a marker of in 
utero androgen exposure, in newborns, and 3) Investigate the prevalence and bioactivity 
of a novel phthalate replacement, DINCH.  
We sampled urine from 378 pregnant women during the second trimester of 
pregnancy living in Charleston, SC and measured the following eight phthalate 
metabolites and three DINCH metabolites by LC-MS/MS: monobutyl phthalate (MBP), 
monobenzyl phthalate (MBzP), mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-
oxohexyl) phthalate (MEOHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), 
monoethyl phthalate (MEP), monoisobutyl phthalate (MiBP), monomethyl phthalate 
(MMP), cyclohexane-1,2-dicarboxylic acid-mono(hydroxy-isononyl) ester (OH-
MINCH), cyclohexane-1,2-dicarboxylic acid-mono(oxo-isononyl) ester (oxo-MINCH), 
and cyclohexane-1,2-dicarboxylic acid-monocarboxy isooctyl ester (cx-MINCH). We 
prospectively measured anopenile (APD) and anoscrotal (ASD) distances from 171 boys 
and anoclitoral (ACD) and anofourchette (AFD) distances from 128 girls at delivery. 
xvi 
 
Sociodemographic factors and clinical data were collected from questionnaires and 
delivery records. DINCH estrogenic and progestogenic activity was measured using in 
vitro transactivation assays. 
Phthalate metabolites were detected in 100% and OH-MINCH was detected in 
98% of urine samples. Sociodemographic characteristics associated with elevated 
phthalate concentrations included being unmarried, less educated, having a low income, 
higher BMI, and/or being African American. We identified inverse associations between 
phthalates and APD among boys and a longer ASD with higher concentrations of four 
phthalates, without evidence for racial interaction. Among girls, we found no association 
for AFD, but detected racial interactions, in which ACD was longer for Caucasians and 
shorter for African Americans, following exposure to four phthalate metabolites. DINCH 
metabolites did not exhibit estrogenic or progestogenic activity. 
Results from this study provide evidence for significant racial and demographic 
variations in phthalate exposure. Our findings also suggest race and sex play important 
roles in phthalate-associated reproductive developmental toxicity. Finally, phthalates are 
being replaced by alternatives whose safety has not been thoroughly investigated. 
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Chapter 1. General Introduction 
1.1 The Endocrine System 
 The endocrine system is made up of glands throughout the body that secrete 
hormones directly into the circulatory system targeting specific organs. The major 
endocrine glands and organs are the hypothalamus gland, pituitary gland, pineal gland, 
thyroid gland, parathyroid glands, adrenal glands, pancreas, and ovaries in females or 
testicles in males. These glands are responsible for the regulation of metabolism, growth 
and development, reproduction, heart rate, sleep, mood, and countless other activities. 
The nervous system, as well as chemical receptors and hormones, control endocrine 
gland stimulation, which in turn regulates the body’s organs to maintain homeostasis. 
 
1.2 Endocrine Disrupting Chemicals 
The term ‘endocrine disruptor’ was coined in 1991 at the Wingspread Conference 
in Racine, Wisconsin. Evidence of manmade chemicals interfering with ordinary 
activities of the endocrine system had been suspected for some time, but finally the 
conferees concluded that “a large number of man-made chemicals that have been released 
into the environment...have the potential to disrupt the endocrine system of animals, 
including humans” (Markey et al. 2002). The U.S. Environmental Protection Agency 
(EPA) subsequently defined an endocrine disrupting chemical (EDC) as “an exogenous 
agent that interferes with the synthesis, secretion, transport, binding, action, or 
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elimination of natural hormones in the body which are responsible for the maintenance or 
homeostasis, reproduction, development and or behavior” (Kavlock et al. 1996).  
Many consider EDCs to be a relatively new problem; however, they have been a 
topic of discussion long before 1991. Our ancestors used environmental EDCs in the 
forms of herbal medicines to modify hormonal processes. Ginseng, a phytoestrogen, has 
been used for over 2000 to balance hormonal levels of women and promote longevity 
(Attele et al. 1999). Historically, livestock have also been affected by phytoestrogens. 
Farmers reported reproductive complications in cows and sheep grazing in clover 
pastures that were later found to contain estrogenic compounds (Adams 1995).  
The past century has witnessed the introduction of many man-made EDCs. 
Perhaps the most well-known synthetic EDC is diethylstilbestrol (DES), an estrogen 
mimic that was first introduced as a drug in 1938 in hopes of preventing miscarriages and 
preterm births. Not only was the drug largely ineffective for those purposes, but 
daughters of the women who took DES were more likely to develop a rare vaginal cancer 
and suffer from infertility (Reed et al. 2013). The U.S. Food and Drug Administration 
(FDA) eventually recommended that physicians stop prescribing DES in 1971. The 
production of synthetic chemicals, many of which act as EDCs, erupted around and after 
World War I, and global chemical production continues to increase at a rate of 3% per 





One important group of chemicals with known EDC properties are the plasticizer 
compounds known as phthalates. Phthalates were introduced into commerce in the 1930s 
and are used to solubilize and stabilize polymers (Table 1.1). They impart flexibility and 
durability to plastics such as polyvinyl chloride (PVC) and ensure long-lasting fragrance 
in personal care products (PCPs). Phthalates are manufactured by reacting phthalic 
anyhydride with alcohol resulting in esters of phthalic acid. Low molecular weight 
phthalates, which consist of a backbone of seven carbon molecules or less (eg: diethyl 
phthalate [DEP] and dibutyl phthalate [DBP]), are often used in PCPs, cosmetics, 
adhesives, solvents, inks, and pharmaceuticals (Duty et al. 2005, Braun et al. 2014). High 
molecular weight phthalates, which have more than seven carbon molecules (eg: 
diethylhexyl phthalate [DEHP] and diisononyl phthalate [DiNP]), serve in plastic 
applications as building materials, food packaging, toys, vinyl products, and medical bags 
and tubing (EPA 2007, Zota et al. 2014). Because they are not chemically bound to the 
products they are in, phthalates commonly leach out into the environment, resulting in 
ubiquitous exposure (Heudorf et al. 2007).  
 
1.4 Phthalate Prevalence 
Phthalates made up approximately 70% of the 8.4 million ton global plasticizer 
consumption in 2014 and are the most commonly produced plasticizers in the world 
(Bizzari et al. 2015). In the U.S., over 470 million pounds of phthalates are produced or 
imported every year (EPA 2006). It comes as no surprise that phthalate exposure to 
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humans is widespread in the U.S. and beyond (Kasper-Sonnenberg et al. 2012, Han et al. 
2014, CDC 2015, Dewalque et al. 2015). The most commonly used phthalate is DEHP, 
with 194 million pounds produced in the U.S. in 2005 (NTP 2016). Vinyl products 
regularly contain up to 40% DEHP, but one study reported that DEHP concentrations in 
PVC medical tubing could be as high as 80% (Tickner et al. 2001). In addition to being 
one of the most prevalent phthalates, DEHP is also one of the most toxic and 
carcinogenic phthalates (Gray et al. 2000, ATSDR 2002, Specht et al. 2014). 
Recent reports suggest that exposure to certain phthalates including DEHP, butyl 
benzyl phthalate (BBzP), and DBP has been decreasing over the past decade following 
government regulation, while exposure to others (DiNP, DBP) is increasing (Silva et al. 
2013, Zota et al. 2014, Calafat et al. 2015). Average human urinary concentrations reflect 
the high use of phthalates in commercial products and typically range from < 1 ng/mL for 
less common metabolites such as monomethyl phthalate (MMP), to 80 ng/mL or more for 
monoethyl phthalate (MEP) and more prevalent metabolites (CDC 2015). Phthalates 
were also found to be present in over 99% of U.S. pregnant women, which raises concern 
for fetal exposure during critical periods of genital development (Woodruff et al. 2011). 
In addition to urine, phthalates have been identified in plasma, breast milk, semen, saliva, 
amniotic fluids, and fetal cord blood, (Jonsson et al. 2005, Main et al. 2006, Hines et al. 
2009, Huang et al. 2009, Lin et al. 2011), and are capable of crossing the placental and 




1.5 Routes of Exposure 
For the general population, the most likely routes of exposure to phthalates are 
ingestion, inhalation, and dermal absorption (Meeker et al. 2009a). Phthalates, especially 
DEHP and those of high molecular weight, are widely present in U.S. foods (Schecter et 
al. 2013, Trasande et al. 2013). Phthalates from the environment accumulate in meat, 
fish, and dairy products (Adibi et al. 2003), and other foods are exposed during 
processing and packaging (Cao 2010). Phthalates are slightly lipophilic and readily 
migrate from plastic food containers and wraps into the fat of foods in contact with 
plastics, especially when heated (Cao 2010, Erythropel et al. 2014). Fast food and 
pharmaceuticals are also significant dietary sources of phthalate exposure (Hauser et al. 
2004, Hernandez-Diaz et al. 2009, Zota et al. 2016). Household dust and off gassing 
from home materials such as vinyl flooring and shower curtains contribute to phthalate 
inhalation exposures (Guo et al. 2011, Langer et al. 2014, Just et al. 2015). 
Dermal absorption of phthalates through the use of PCPs and cosmetics is 
especially concerning. Not only are these chemicals directly applied to the skin, but the 
products are often unregulated and generally used in larger quantities by women 
compared to men. Additionally, most PCPs and cosmetics are marketed to vulnerable 
populations such as teenagers and women of childbearing age. Low molecular weight 
phthalates are often included in PCP formulations in order to preserve color and 
fragrance, denature alcohol, and impart smooth texture. In a survey of 2,300 men and 
women, the average person reported using nine PCPs daily, with 25% of women using 15 
or more each day (EWG 2012). The most prevalent phthalate in PCPs, DEP, was 
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positively identified in 103 of 252 products tested (Koniecki et al. 2011) and is present in 
nearly all perfumes (Al-Saleh et al. 2015). As such, women who use perfume have nearly 
three times higher MEP concentrations (the DEP metabolite) than women who do not use 
perfume (Parlett et al. 2013). The use of mouthwash and sunscreen has also been 
associated with higher phthalate concentrations (Ferguson et al. 2016), as have hair 
spray, nail polish, deodorant (Parlett et al. 2013), cologne, and aftershave (Duty et al. 
2005).  
While phthalate exposure is ubiquitous, larger bioburdens have been associated 
with people of certain ethnicities, demographics, physical build, and socioeconomic class. 
Infants and children commonly have higher phthalate concentrations than adults due to 
additional exposures from mouthing of fingers and plastic toys, breast milk, and formula 
(Koch et al. 2004, Koch et al. 2005, Sorensen 2006, Sathyanarayana 2008, Wittassek et 
al. 2011). The hospitalized and sick are also at risk of acute phthalate exposures, as most 
medical bags, tubing, and medications contain alarming concentrations of DEHP (Hauser 
et al. 2004, Hernández-Díaz et al. 2013). Metabolites of DEHP have been reported at 
concentrations well above safe limits in critically ill neonates receiving medical care 
(Sathyanarayana 2008, Mallow et al. 2014). Additionally, there is evidence that females 
(Silva et al. 2004a, Trasande et al. 2013), non-white populations (Kobrosly et al. 2012, 
Trasande et al. 2013), those of heavier build (Hatch et al. 2008, Teitelbaum et al. 2012), 
and those of lower socioeconomic status (Kobrosly et al. 2012, Valvi et al. 2015) exhibit 




1.6 Phthalate Metabolism 
With a biological half-life ranging from hours to several days, phthalates are 
metabolized and eliminated from the body rather quickly and do not accumulate 
(Anderson et al. 2001). However, since humans are exposed continuously, phthalates are 
considered to be pseudo-persistent. Phthalate metabolism is dependent on the size and 
structure of the parent diester compound. Phthalate diesters typically undergo metabolism 
in two steps: phase I hydrolysis followed by phase II conjugation (Figure 1.1). The first 
step, in which the parent diester is hydrolyzed into a monoester phthalate metabolite, is 
catalyzed by lipases and esterases in the intestine and liver (Calafat et al. 2006, Rusyn et 
al. 2006). Usually, this first step acts to detoxify exogenous compounds; however, in 
vitro and in vivo studies in rodents report that the phthalate monoesters influence 
testicular atrophy more so than the parent diesters (Heindel et al. 1992).  
In phase II metabolism, the enzyme uridine 5’-diphosphoglucuronyl transferase 
catalyzes the conjugation of the phthalate monoester with a hydrophilic glucuronide 
group, thus effectively making the compounds water-soluble and flagging them for 
removal through urine (Frederiksen et al. 2007). Shorter chained, lower molecular 
weight, and polar diesters are sometimes excreted as hydrolyzed monoesters following 
phase I metabolism, while higher molecular weight phthalates typically undergo phase I 
and phase II biotransformation before being excreted into urine. Due to this rapid 
metabolism, it is common practice to measure the urinary monoester metabolites as 
biomarkers of phthalate exposure, as the monoesters are dominant in urine and phthalate 
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diesters may be present in laboratory materials used to process biological samples prior to 
analysis. 
 
1.7 Phthalate-Mediated Endocrine Disruption in Rodents 
In male rodent models, phthalates produce antiandrogenic effects by reducing the 
expression of enzymes and proteins involved in steroidogenesis, ultimately inhibiting 
Leydig cell production of testosterone (Martinez-Arguelles et al. 2013). The DEHP 
metabolite mono-(2-ethylhexyl) phthalate (MEHP) is also known to act on Sertoli cells to 
increase testicular germ cell apoptosis (Yao et al. 2009). Phthalate exposure during the 
fetal period leads to abnormal sexual development in males, including reduced 
testosterone levels, testicular atrophy, feminized anogenital distance (AGD), germ cell 
loss, the presence of areolas or nipples, absent or underdeveloped epididymis, Sertoli cell 
abnormalities, and hypospadias (Mylchreest et al. 1998, Gray et al. 2000, Foster et al. 
2001, McKee et al. 2006). There is also support for DEHP disruption of luteinizing 
hormone formation that is independent of the classical steroid biosynthetic pathway 
(Martinez-Arguelles et al. 2013). Other studies of chronic exposure have demonstrated 
that in addition to testicular injury, phthalates can lead to liver injury, cancer, and 
teratogenicity (Gray et al. 2000, Lovekamp-Swan et al. 2003, Bility et al. 2004).  
Phthalates impact steroidogenesis in such a way that estrogen production is also 
disrupted. In females, DEHP has been shown to reduce estradiol levels by decreasing 
aromatase expression (Lovekamp et al. 2001). Other studies have confirmed these 
findings and have also demonstrated that phthalate exposure results in reduced expression 
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of cytochrome P450 17A1, progesterone, and gonadotropin receptors in the adult ovary, 
which inhibit estrogen production and reproductive performance (Pocar et al. 2012, Guo 
et al. 2015, Hannon et al. 2015, Hannon et al. 2015). Additionally, there is evidence that 
phthalate exposure can suppress granulosa cell proliferation, increase preantral follicle 
number, inhibit antral follicle functionality, alter mammary gland cells, and lead to 
breeding abnormalities (Hannon et al. 2015, Li et al. 2015, Niermann et al. 2015, Wang 
et al. 2016). 
Other targets of phthalate exposure include the aberrant transportation of 
cholesterol into the mitochondria, which is the rate-limiting step of steroidogenesis, 
(Martinez-Arguelles et al. 2013), peroxisome proliferator-activated receptor gamma 
binding (Lovekamp-Swan et al. 2003, Xu et al. 2010), and gene expression involved in 
regulatory functions of the adrenal gland (Martinez-Arguelles et al. 2015). Taken 
together, phthalates act on multiple pathways involved in maintaining steroid 
homeostasis, depending on the phthalate, dose, and timing of exposure. 
 
1.8 Phthalate-Mediated Endocrine Disruption in Humans 
Similar to rodent models, antiandrogenic effects of phthalates have also been 
documented in humans. Phthalate exposure has been associated with abnormalities in 
male reproductive development, including decreased testosterone levels (Main et al. 
2006, Pan et al. 2006, Meeker et al. 2009b, Mendiola et al. 2011, Mendiola et al. 2012, 
Ferguson 2014), reduced penile size, incomplete testicular descent (Swan 2008), 
cryptorchidism (Swan 2008), gynecomastia (Durmaz et al. 2010), and a shortened AGD 
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(Swan et al. 2005, Swan 2008, Suzuki et al. 2012, Bustamante-Montes et al. 2013, 
Bornehag et al. 2014, Swan et al. 2015). There is also evidence that phthalates impact 
sperm quality and fertility (Jonsson et al. 2005, Hauser et al. 2006, Liu et al. 2012, 
Tranfo et al. 2012, Han et al. 2014, Specht et al. 2014, Axelsson et al. 2015). 
Additionally, offspring from mothers occupationally exposed to phthalates have been 
associated with increased risk of hypospadias (Ormond et al. 2009) and cryptorchidism 
(Wagner-Mahler et al. 2011). 
Adverse reproductive health effects following phthalate exposure is less studied in 
females. Still, phthalate exposure has been associated with premature thelarche (Colón et 
al. 2000, Chou et al. 2009, Wolff et al. 2010), and increased odds of endometriosis 
(Cobellis et al. 2003, Reddy et al. 2006, Weuve et al. 2010) and uterine fibroids (Huang 
et al. 2010, Weuve et al. 2010). Phthalate exposure has also been associated with 
pregnancy complications, including increased time to pregnancy (Burdorf et al. 2011), 
pregnancy loss (Toft et al. 2012), preterm birth (Meeker et al. 2009c, Ferguson et al. 
2014), and decreased gestational age at birth (Wolff et al. 2008, Whyatt et al. 2009). 
More recently, researchers discovered a correlation between MEP concentrations and the 
incidence of breast cancer in Mexican women (López-Carrillo et al. 2010), and an in 
vitro study demonstrated that phthalates can promote tumor growth of estrogen receptor-
negative breast cancer cells (Hsieh et al. 2012). 
In addition to reproductive toxicity, phthalates can also influence more 
widespread health outcomes. Phthalates have been associated with diabetes (James-Todd 
et al. 2012b, Lind et al. 2012, Huang et al. 2014, Legler et al. 2015), obesity (Desvergne 
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et al. 2009, Wang et al. 2013, Buser et al. 2014), thyroid disorders (Huang et al. 2007, 
Meeker et al. 2007), and inflammation (Latini et al. 2005). Pulmonary system 
dysfunction such as allergies, rhinitis, and asthmatic reactions have also been associated 
with phthalate exposure (Bornehag et al. 2004, Kolarik et al. 2008, Shin et al. 2014), and 
DEHP exposure results in increased levels of reactive oxygen species (Martinez-
Arguelles et al. 2013, Cho et al. 2015). Following fetal exposure to phthalates, children 
may suffer from neurological effects such as autism (Kalkbrenner et al. 2014), 
masculinized play behavior in girls (Barrett et al. 2014), and adverse effects on mental 
and motor development (Engel et al. 2010, Whyatt et al. 2012). 
In addition to the direct effects resulting from phthalate exposure, phthalates can 
act as modulators of epigenetics, the study of heritable changes in gene expression 
without changing DNA sequences. In an in vitro study of human breast cancer cells, 
treatment with benzyl butyl phthalate (BzBP) led to demethylation of estrogen receptor 
promoter-associated CpG islands, suggesting that BzBP can alter estrogen receptor 
mRNA expression via abnormal DNA methylation (Kang et al. 2005). Another study 
demonstrated that DEHP exposure can alter the DNA methylation of imprinting genes in 
fetal mouse germ cells and in the oocytes of both the F1 and F2 generations, proposing 
that long-term heritable effects can be caused by phthalate exposure (Li et al. 2014).  
 
1.9 Phthalate Regulation 
Several countries have partially acknowledged the potential harm caused by 
phthalates and have instituted regulations aimed at reducing certain exposures. Since oral 
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and dermal exposures are easiest to control, these are the focus of most regulations. The 
U.S. first applied phthalate regulations to products intended for children. The Consumer 
Product Safety Improvement Act of 2008 banned six phthalates (DEHP, DBP, BzBP, 
DINP, diisodecyl phthalate [DIDP], and di-n-octyl phthalate [DnOP]) from making up 
greater than 0.1% in toys and child care articles (CPSC 2008). Several state governments, 
including California, Vermont, and Washington have established standards for the 
content of certain phthalates in children’s articles (EPA 2012). Despite the concern for 
child exposures, there are currently no regulations for phthalate-containing medical 
tubing in the neonatal intensive care environment; however, several hospitals are 
converting to alternative products following mounting public awareness and pressure 
from nonprofit groups. The efficacy and safety of these alternative products (including 
adipates, citrates, terephthalates, and trimellitates) remains unknown. 
The EPA, which evaluates potentially harmful chemicals under the Toxic 
Substances Control Act, has created limited regulatory standards for phthalates. Eight 
phthalates (DBP, diisobutyl phthalate [DIBP], BzBP, di-n-pentyl phthalate [DnPP], 
DEHP, DnOP, DINP, and DIDP) were included in an Action Plan (EPA 2012), outlining 
risks and potential actions recommended to address risks. As a result, the EPA issued a 
rule in 2014 requiring manufacturers to notify the EPA if they are going to use DnPP in a 
product so they can deem it necessary. Under the Safe Drinking Water Act, it was 
mandated in 1994 that DEHP may not be present in drinking water in at greater than 6 
µg/L. The Clean Air Act lists DEHP and DBP as hazardous air pollutants. However, 
water supplies and air are not routinely monitored for phthalates. The Occupational 
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Safety and Health Administration has established standards for phthalates in the 
workplace to include a maximum average of 5 mg/m3 DEHP in air in the workplace 
during an 8-hour shift. 
The FDA is the regulatory agency overseeing phthalates in food contact 
substances, cosmetics, pharmaceuticals, and medical devices. In 2008, the FDA began 
conducting a comprehensive inventory of regulated products that contain phthalate but no 
regulations have been released. In 2012, the agency recommended avoiding the use of 
DEHP and DBP in drugs and biologic products (HHS 2012). Cosmetic products and 
ingredients used therein are not subject to regulation or approval by the FDA before 
entering the market. Currently, the FDA has stated that they do not have evidence that 
phthalates used in cosmetics pose a safety risk (FDA 2016). In response to growing 
public concern and consumer demands, some major companies such as Revlon are 
voluntarily phasing out the use of phthalates in their products (Calafat et al. 2015, Kessler 
2015). The FDA has issued no regulations on phthalates in food contact materials, but 
they issued a guidance in 2012 establishing an allowable level of 6 µg/L MEHP in bottled 
water in compliance with the Safe Drinking Water Act (FDA 2012).  
Operating under the precautionary principle, the European Union (EU) has 
regulated the use of some phthalates in children’s toys since 1999. In 2005, DEHP, 
BzBP, and DBP were banned from all toys permanently, and DINP, DIDP, and DnOP 
were banned in toys that can be placed in the mouth (European Union 2005). The 
amounts of these phthalates cannot be greater than 0.1% of the plasticized part of the toy. 
In 2008, measures were implemented to limit the use of phthalates in food contact 
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materials (overall migration limit of 60 mg/kg food) and the European Food Safety 
Authority (EFSA) established conservative tolerable daily intake limits for DBP, BzBP, 
DEHP, DINP, and DIDP (EFSA 2006). Regulation enforcement is an issue within the 
EU; in two successive studies, a significant proportion of food contact materials tested 
were well over the limits set by the EFSA (Petersen et al. 2010). Unlike the U.S., the EU 
has banned the sale of cosmetics containing five phthalates (DBP, DEHP, BzBP, DnPP, 
and DIPP [Diisopentyl phthalate]) since 2004 (European Union 2009, Al-Saleh et al. 
2015, Bao et al. 2015). There are also limitations to phthalate use in medical device 
applications, including ensuring that any risk, such as from exposure to DEHP, is 
outweighed by the anticipated benefits to the patient. Some medical devices must be 
labelled as containing certain phthalates, such as DEHP. In fact, DEHP is now classified 
as carcinogenic, mutagenic, or toxic to reproduction under the European regulations 
(Eljezi et al. 2017) 
Canada strives to keep up with regulatory precedents set by the U.S. and EU, 
proposing in 2009 to harmonize phthalate regulations. Other countries that have 
established limits for phthalates in toys and children’s products include France, 
Argentina, Brazil, Australia, China, and Japan. Japan, China, and South Korea have 
limited phthalates in food contact materials since 2000 and 2008 (Petersen et al. 2010, 
Serrano et al. 2014). However, China is the largest plasticizer market and accounted for 




1.10 Phthalate Replacement 
Phthalates are ubiquitous because they increase the flexibility and durability of 
plastics and are affordable. With scientific evidence and public awareness of endocrine 
disruption mounting, there is growing pressure for companies to remove phthalates from 
their products. Unfortunately, phthalates are often replaced with similar chemicals of 
unknown endocrine activity, which can lead to ‘regrettable substitution’. One of the most 
commonly encountered replacements is di(isononyl)cyclohexane-1,2-dicarboxylate 
(DINCH). Currently, little is known about the prevalence of human exposure to this 
replacement; however, recent reports suggest concentrations of urinary DINCH 
metabolites are increasing. Between 2002 and 2012, the percentage of urine samples with 
detectable concentrations of DINCH metabolites increased from 0% to 21% in the U.S. 
and to 98% in Germany (Silva et al. 2013, Schütze et al. 2014). Other non-phthalate 
plasticizers include terephthalates, epoxy, aliphatics, citrates, and benzoates (Figure 1.2). 
The bioactivity and endocrine disrupting potential of DINCH and most phthalate 
replacements remain unknown.  
 
1.11 Significance 
Barker and colleagues (1986) were some of the first to identify a connection 
between fetal experiences and the onset of disease later in life. He noticed that regions in 
England with the highest incidences of infant mortality also had the highest rates of death 
from coronary heart disease decades later. Barker hypothesized that low birthweight 
babies who survived infancy and childhood might be at increased risk for coronary heart 
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disease later in life. This hypothesis evolved into the developmental origins of health and 
disease hypothesis, also known as the “Barker hypothesis”. 
The Barker hypothesis has been extended to include prenatal insults from EDCs, 
now amounting to nearly 800 suspected chemicals (Bergman et al. 2013). In support of 
the Barker hypothesis is the fact that many endocrine-related diseases and hormone-
dependent cancers (breast, endometrial, ovarian, prostate, testicular, and thyroid) are 
paralleling the rise of EDCs (WHO et al. 2012). The number of people with diabetes has 
risen from 108 million in 1980 to 422 million in 2014 (WHO 2016). Childhood cancer 
incidence rates have increased by 0.6% per year since 1975, and rates of thyroid cancer 
have increased by 5.1% per year from 2003 to 2012 (ACS 2016). Testicular germ cell 
cancers have been increasing over the past 40 to 50 years by as much as 400% in most 
industrialized countries, where they are the most common cancers in young men aged 20 
to 45 (Huyghe et al. 2003, Richiardi et al. 2004). Breast cancer incidence rates are 
increasing as well in almost all industrialized countries (Héry et al. 2008). 
Bergman and colleagues (2013) summarize that semen quality is suffering in 
many populations and contributing to increases in fertility issues. Studies on Nordic, 
Baltic, German, Spanish and Japanese men demonstrate that 20-40% of young men have 
semen quality below what is considered to be compatible with good fecundity (40 
mill/mL) (Guzick  et al. 2001, Skakkebaek 2010). Between 3.5 and 16.7% of couples in 
developed countries and 6.9 to 9.3% of couples in less developed countries are unable to 
conceive (Boivin et al. 2007). The U.S. fertility rate has decreased from 3.7% in 1964 to 
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1.9% in 2014 (World Bank 2016), and the U.S. preterm birth rate has increased by more 
than 30% since 1981 (Institute of Medicine 2007, Martin et al. 2009).  
While certainly not acting alone, phthalates have been associated with most of 
these adverse health outcomes. It has also been suggested that phthalates contribute to 
development of the testicular dysgenesis syndrome, a hypothesis that proposes that 
cryptorchidism, hypospadias, impaired spermatogenesis, and testis cancer may be 
manifestations of disturbed prenatal testicular development (Bay et al. 2006). More 
specifically, phthalates have also been implicated in a syndrome of male reproductive 
abnormalities that includes a shortened AGD, hypospadias, cryptorchidism, and 
malformations of the epididymis, vas deferens, seminal vesicles, and prostate, termed the 
‘phthalate syndrome’ (Foster 2006, Welsh et al. 2008); recently, the human analogue of 
this syndrome was identified in a pregnancy cohort study (Swan 2008). 
The overarching goal of the research presented in this dissertation is to determine 
how prevalent phthalate exposure is in pregnant women locally and how this exposure 
might influence reproductive health and success. In Chapter 2, I assess phthalate 
prevalence and predictors in a population of pregnant women receiving care at the 
Medical University of South Carolina. Previous human studies of prenatal phthalate 
exposure have been conducted in relatively homogenous populations, whereas this study 
integrates racial diversity. I identify several risk factors that can be used to predict 
women who may experience above average phthalate concentrations. With the 
acknowledgment of factors contributing to higher phthalate prevalence comes an 
opportunity to reduce exposure, as most exposure behaviors are modifiable. In Chapter 3, 
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we explore associations between prenatal phthalate exposure and AGD measures in a 
racially diverse population of newborns. AGD is a sexually dimorphic trait that serves as 
an indicator of prenatal androgen exposure, and we use it to monitor potential 
antiandrogenic effects stemming from prenatal phthalate exposure. Despite the growing 
interest in AGD as an indicator of gestational exposure to EDCs, no previous study has 
analyzed the impact of race on the relationship with prenatal phthalate exposures. Lastly, 
I evaluate the prevalence of a phthalate replacement chemical, DINCH, in a population of 
pregnant women and determine if DINCH and its metabolites exhibit properties of 
endocrine disruption in Chapter 4. By being proactive about assessing replacement 
chemicals, we hope to prevent a case of regrettable substitution.  
 
1.12. Hypotheses 
As part of our investigations, we test the following hypotheses: 
Chapter 2: Prevalence and predictors of phthalate exposure in pregnant women in 
Charleston, SC 
 H1) Phthalate exposure will be prevalent in a local population of pregnant 
women. 
 H2) Phthalate exposure will be higher in African American women, women with 
high BMIs, and women of lower socioeconomic status. 
Chapter 3: Influence of race on prenatal phthalate exposure and anogenital 
measurements among offspring   
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H1) There will be an inverse association between urinary phthalate metabolites 
and AGD in male and female newborns. 
 H2) Associations between urinary phthalate metabolites and AGD in newborns 
will be stronger among African Americans. 
Chapter 4: Assessing the prevalence and bioactivity of a novel phthalate 
replacement chemical, DINCH 
 H1) Urinary DINCH metabolites will be present in our population at low 
concentrations. 





Table 1.1 Phthalate and DINCH urinary metabolites measured in this study. Adapted from Zota et al. (2014). Abbrev = 
abbreviation; MW = molecular weight; KOW = n-Octanol/Water Partition Coefficient. 
 




Monoester metabolite Abbrev Common sources 
Dimethyl phthalate DMP 194.2 1.60 Monomethyl phthalate MMP Insect repellent, 
plastic bottles, food 
Diethyl phthalate DEP 222.2 2.47 Monoethyl phthalate MEP Fragrance, cosmetics, 
medications 
Dibutyl phthalate DBP 278.4 4.50 Monobutyl phthalate MBP Cosmetics, 
medications, food 
packaging, food, PVC 
applications 
    Monoisobutyl phthalate MiBP Cosmetics, food, food 
packaging 
Butylbenzyl phthalate BBzP 312.4 4.73 Monobenzyl phthalate MBzP PVC flooring, food, 
food packaging 
Diethylhexyl phthalate DEHP 390.6 7.60 Mono(2-ethylhexyl) phthalate MEHP PVC applications, 
toys, cosmetics, food, 
food packaging 
    Mono(2-ethyl-5-hydroxyhexyl) 
phthalate 
MEHHP 










Medical devices, toys 
    cyclohexane-1,2-dicarboxylic 
acid-monocarboxy isooctyl ester 
cx-
MINCH 















Figure 1.2. Chemical structures, names, abbreviations, and CAS numbers of non-




Chapter 2. Prevalence and predictors of phthalate exposure in pregnant women in 
Charleston, SC 
2.1 Introduction 
Phthalates are frequently used in consumer products as plasticizers and 
solubilizers. Because they are not chemically bound to those products, phthalates leach 
into the environment, resulting in ubiquitous human exposure. Primary routes of 
phthalate exposure to humans include dietary consumption of contaminated food and 
water (Colacino et al. 2010, Serrano et al. 2014), and skin absorption following the use of 
personal care products (PCPs) (Duty et al. 2005, Guo et al. 2013, Parlett et al. 2013). 
Two phthalates that are of particular concern due to their antiandrogenic properties are 
di-2-ethylhexyl phthalate (DEHP) and dibutyl phthalate (DBP). In addition, due to its 
widespread use in PCPs, the metabolite of diethyl phthalate (DEP), monoethyl phthalate 
(MEP), is generally detected in urine at concentrations five to forty times higher than 
other phthalate metabolites in the U.S. (Silva et al. 2004a, CDC 2017). 
Phthalate exposure is prevalent among pregnant women, raising concern for fetal 
exposure, especially during critical periods of development (Woodruff et al. 2011). In 
utero exposure to select phthalates, as approximated by measuring maternal urinary 
phthalate metabolites, has been associated with adverse pregnancy outcomes, including 
preterm birth and low birth weight (Meeker et al. 2009c, Zhang et al. 2009, Ferguson et 
al. 2014). Additionally, biomarkers of abnormal reproductive development have been 
noted in males following high-level prenatal phthalate exposure, including reduced 
anogenital distance, penile size, testosterone concentrations, and incomplete testicular 
descent (Swan et al. 2005, Main et al. 2006, Swan 2008, Wagner-Mahler et al. 2011, 
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Swan et al. 2015). Recent research suggests that prenatal phthalate exposure may also be 
associated with more expansive health outcomes later in life, including adverse 
neurocognitive development (Engel et al. 2009, Engel et al. 2010, Whyatt et al. 2012, 
Factor-Litvak et al. 2014), asthma (Dodson et al. 2012), diabetes (James-Todd et al. 
2012b), and obesity (Desvergne et al. 2009, Trasande et al. 2013). 
While phthalate exposure is ubiquitous, larger bioburdens have been associated 
with people of certain ethnicities, demographics, physical build, and socioeconomic 
class; however, these trends lack consistency across different studies (Casas et al. 2011). 
Previous surveys of phthalate concentrations in pregnant women have been conducted 
along the West Coast and in the Northeastern U.S.; the Southeast is a region with unique 
culture, climate, diet, lifestyle, and racial makeup that could introduce novel patterns of 
phthalate exposure. Because of the potential adverse health outcomes, it is important to 
further our understanding of patterns and sources of phthalate exposure across all 
populations. The aim of this cross-sectional study was to identify potential predictors of 
phthalate exposure in pregnant women residing in the Charleston, South Carolina 
metropolitan area.  
2.2 Materials and Methods 
Chemicals and Reagents 
Phthalate metabolites, their isotope-labeled internal standards, and 13C4-4-
methylumbelliferone (> 99.9%) were purchased from Cambridge Isotope Laboratories, 
Inc. (Andover, MA, USA).  4-methylumbelliferone (4-MeUmb) and its glucuronide were 
purchased from Sigma Aldrich Laboratories, Inc. (St.Louis, MO, USA). Acetonitrile, 
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water (HPLC grade), and ethyl acetate were purchased from Honeywell Burdick and 
Jackson (Morris Plains, NJ, USA). Ammonium acetate, acetic acid (98% min.), and 
monosodium phosphate monohydrate anhydrous were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA). Phosphoric acid (85%) and formic acid (98% min.) 
were purchased from EMD Millipore (Billerica, MA, USA). β-glucuronidase 
(Escherichia coli-K12) was purchased from Roche Biomedical (Mannheim, Germany). 
All chemicals and reagents were used without further purification. 
Study Population 
From 2011 to 2014, women from the Charleston area who planned to deliver at 
the Medical University of South Carolina (MUSC) were recruited to participate in a 
larger study designed to examine the relationship between maternal phthalate 
concentration and prenatal and neonatal genital measurements. Eligibility criteria to 
participate included being at least 18 years of age, carrying a singleton fetus, and having 
pregnancy dating confirmed by a first trimester ultrasound. Women were excluded if they 
were carrying a fetus with genetic anomalies or aneuploidy, using progesterone or other 
steroids, or had pre-gestational diabetes mellitus, hypo- or hyperthyroidism, or any other 
known endocrine disorders.  
Between 18 and 22 (median = 20) completed weeks of gestation, participants 
answered a study questionnaire, provided a urine specimen, and were evaluated for 
physical condition and relevant pregnancy characteristics. This study and all survey 
protocols were approved by the institutional review board of MUSC. All participants 




Demographic information was obtained through a questionnaire administered to 
women upon enrollment into the study. Clinical data was abstracted from medical 
records. Variables collected and evaluated in this study as potential determinants of 
phthalate exposure included maternal age, BMI, race, parity, tobacco use, medication use, 
prenatal vitamin use, nutritional supplement use, contraceptive choice, marital status, 
education level, employment status, smoking status, annual household income, and 
season and year of sample collection. BMI was calculated from physician-recorded 
height and weight at time of enrollment. Race was self-categorized as either African 
American or Caucasian. Twelve women of other ethnicities were enrolled in the study but 
were removed from analysis due to the small sample size. Maternal education was 
classified into four ordinal categories: less than high school degree, high school graduate 
or equivalent, some college or technical school, and college graduate or above. Marital 
status was classified as two categories: married or living as married, and single (which 
included single, separated, divorced, and widowed). Annual household income was 
classified into four categories for analysis: less than $25,000, $25,000 to $65,000, greater 
than $65,000, and do not know. Age, BMI, and education were treated as continuous 
variables, and race, marital status, and household income were treated as categorical 
variables. 
Sample preparation for phthalate metabolite analysis 
Urine from 378 women was analyzed for eight phthalate metabolites, including 
monomethyl phthalate (MMP), MEP, monobutyl phthalate (MBP), monoisobutyl 
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phthalate (MiBP), monobenzyl phthalate (MBzP), mono(2-ethylhexyl) phthalate 
(MEHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-ethyl-5-
hydroxyhexyl) phthalate (MEHHP). Urine specimens were collected in sterile glass jars 
at MUSC and transferred to the Hollings Marine Laboratory (Charleston, South Carolina) 
for analysis. After measuring specific gravity (SG) at room temperature using a handheld 
refractometer (Atago U.S.A., Inc., Bellevue, WA, USA), urine was divided into 1 mL 
aliquots and stored under appropriate conditions (-20° C) until analysis.  
Stock solutions of phthalate metabolites, 4-MeUmb, and isotopically-labeled 
metabolites and 4-MeUmb were prepared in Millipore water and stored at 4°C in Teflon-
capped glass bottles. The calibration standards, containing native and isotopically-labeled 
phthalate metabolites and 4-MeUmb were prepared in 10% aqueous acetonitrile from 
stock solutions to create ten unique standard solutions and stored at 4°C in Teflon-capped 
glass tubes until use. 
A standard solution of 4-MeUmb glucuronide (2 μg/mL) was prepared in water 
and added to all samples. The 4-MeUmb/13C4 4-MeUmb peak area ratio was monitored to 
check the extent of the deconjugation reaction with β-glucuronidase. Quality control 
(QC) materials were prepared from a urine pool obtained from multiple anonymous 
donors and was enriched with native phthalate metabolites to resemble an ‘average’ 
concentration.  
Extraction and analysis methods were based on those previously developed by the 
U.S. Centers for Disease Control and Prevention, described elsewhere (Silva et al. 
2004b). Urine was thawed, vortex-mixed, and aliquoted (1 mL) into a glass culture tube. 
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The urine sample was spiked with the internal standard containing a mixture of 
isotopically-labeled analytes (50 μL), 2 μg/mL 4-MeUmb glucuronide solution (25 μL), 
and 2% β-glucuronidase in ammonium acetate buffer (255 μL, pH 6.5/1M). The sample 
was incubated at 37 °C for 90 min to deconjugate the glucuronidated phthalate 
metabolites. The urine sample was then placed on the RapidTrace Station (Zymark 
Corporation, Hopkinton, MA, USA) for the automated solid phase extraction procedure. 
The solvent lines were purged with methanol before each extraction. Polymeric sorbent-
filled cartridges (60 mg, 3 mL; Bond Elut NEXUS, Agilent Technologies, Santa Clara, 
CA, USA) were conditioned with 1 mL acetonitrile followed by 1 mL pH 2 phosphate 
buffer (0.14 M NaH2PO4 in 0.85% H3PO4) at 1 mL/min. Urine samples were loaded onto 
the cartridge at 1 mL/min. The column was then rinsed with 2 mL of 0.1 M formic acid 
followed by 1 mL of water. Cartridges were dried with air for 0.5 min. Analytes were 
eluted with 1 mL acetonitrile followed by 1 mL ethyl acetate at 1 mL/min. The eluates 
were transferred to a TurboVap evaporator (Zymark Corporation, Hopkinton, MA, USA) 
and evaporated to dryness at 55°C under a stream of dry nitrogen. The residue was 
resuspended in 200 μL of Millipore water for analysis. 
Instrumental analysis of phthalate metabolites 
The analysis was performed using an Agilent 1100 Series compartmentalized high 
pressure liquid chromatography system (Santa Clara, CA, USA) coupled to an API 4000 
triple quadrupole mass spectrometer (Applied Biosystems/MDS Sciex, Framingham, 
MA, USA) with electrospray ionization interface. The system was controlled by Analyst 
software, version 1.5.2 (Sciex, Framingham, MA). The autosampler tray was set to 10°C, 
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and 10 μL of the deconjugated urine sample was injected using the autosampler with 
syringe washes between injections. Chromatographic resolution was accomplished using 
a 3 µm, 150 mm x 2.1 mm Betasil phenyl column (Thermo Fisher Scientific, Waltham, 
MA, USA), with a solvent gradient from 25% mobile phase A (0.1% acetic acid in 
acetonitrile) and 75% mobile phase B (0.1% acetic acid in water) to 100% mobile phase 
A before reverting back to primary conditions for 10 min at a flow rate of 0.35 mL/min 
(Table 2.1). The mass spectrometers were tuned and optimized for each analyte. Ion 
transitions were monitored for each analyte in multiple reaction monitoring mode (Table 
2.2).  
Isotopically-labeled internal standards were used along with conjugated internal 
standards to increase precision and accuracy of the measurements. Standard QC and 
reagent blank samples were included in each analytical batch along with participant 
samples. A batch was re-run if any one QC measurement fell outside the 99% confidence 
interval or if two consecutive QC samples fell outside of the 95% confidence interval. A 
NIST standard reference material (SRM 3673, Organic Contaminants in Non-Smokers’ 
Urine) was regularly analyzed alongside samples and measured phthalate values were 
compared to the certified values to ensure measurement precision. In addition to 
analyzing eight individual phthalate metabolites, molar sums of the three measured 
DEHP metabolites were also calculated: ∑DEHP = (MEHP*(1/278)) + (MEOHP*(1/292) 




The limit of detection (LOD) for each metabolite was estimated as the mean of 
the control blanks plus three times the standard deviation of the mean, or the lowest 
detectable calibrant, whichever was higher. Urinary concentrations of phthalate 
metabolites below the LOD were assigned a value equal to half the LOD for statistical 
analysis. Specific gravity was used to adjust for urine dilution according to the following 
formula: Pc = P((1.016 – 1)/(SG – 1)) where Pc is the SG-corrected phthalate 
concentration (ng/mL), 1.016 is the mean SG for all participant urine samples, and SG is 
the individual specific gravity of urine (Boeniger et al. 1993). The concentrations of all 
phthalate metabolites were natural log-transformed in order to meet the assumptions for 
statistical analysis. We assessed univariate associations between individual covariates and 
phthalate concentrations by Pearson correlations, Student’s t-test, or one-way analysis of 
variance (ANOVA) as appropriate.  
To evaluate the impact of clinical and sociocultural factors on phthalate 
concentrations, we employed multiple linear regression models that included a priori-
selected predictors consistently reported in the literature as associated with phthalate 
exposure (Koo et al. 2002, Casas et al. 2011, Kobrosly et al. 2012, Valvi et al. 2015). 
These variables include maternal age, race, education, and household income as a proxy 
for socioeconomic status (SES), as well as BMI during the current pregnancy. Other 
variables evaluated included parity, smoking status, medication use, prenatal vitamin use, 
nutritional supplement use, contraceptive choice, and season and year of enrollment, but 
these variables were not incorporated into the final model due to lack of significance in 
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univariate analyses. Race was strongly associated with other independent variables in the 
analysis and modified their relationships with phthalate concentrations; therefore, we also 
conducted the analysis stratified by race. All statistical analyses were performed using 
IBM SPSS Statistics, version 22 (IBM Corp., Armonk, NY, USA) with the significance 
level set at α = 0.05. 
2.3 Results 
Study Population 
Descriptive statistics of the clinical and sociocultural characteristics are presented 
in Table 2.3 for the population overall and by race. Of the women enrolled in the study, 
49.2% were African American and 50.8% were Caucasian. The median (interquartile 
range) age of all participants was 27 (8) years and the second trimester BMI was 27.2 
(8.5). Overall, the women enrolled were well educated (over 67% had at least some 
college education) and nonsmokers. Racial differences emerged for several variables; in 
particular, a greater percentage of Caucasian women were more likely to be married 
(83.2%), have a college education (63%), and earn at least $65,000 per year (45.9%) 
compared to African American women (25.1%, 21.8%, and 2.9%, respectively).    
Phthalate Prevalence 
Every phthalate metabolite measured in this study was detected at levels above 
the LOD in at least 93% of urine samples (Table 2.4). MEHHP and MiBP were present in 
100% and MEHP, MEOHP, MBP, MBzP, and MEP were present in over 95% of 
samples. The least prevalent metabolite was MMP, which was detected in 93.7% of 
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samples. Both SG-adjusted and unadjusted geometric means and 95% confidence 
intervals (CIs) of the eight phthalate metabolites are presented in Table 2.4. Consistent 
with previous studies and the National Health and Nutrition Examination Survey 
(NHANES) concentrations from 2011 to 2012 (CDC 2017), concentrations of MEP were 
noticeably higher than any other metabolite. The two metabolites with lowest 
concentrations in both this study and in NHANES were MEHP and MMP (CDC 2017). 
Urinary phthalate metabolites displayed significant and weak to strong positive 
correlations with each other (p < 0.05), ranging from r = 0.11 for MEP with MEHP, to r = 
0.97 for MEOHP with MEHHP and ∑DEHP (Table 2.5). 
Univariate Analysis 
Other studies have found phthalate concentrations to be associated with certain 
demographics. Initially, univariate analyses were conducted to determine if phthalate 
concentrations were associated with age, BMI, race, education, marital status, or 
household income in our study population (Table 2.6).   
We found a significant inverse correlation between age and phthalate 
concentrations for four metabolites (MBzP, MEHP, MiBP, and MEP), and a significant 
positive correlation between BMI and phthalate concentration for all but two metabolites 
(MEHP and ∑DEHP; p < 0.05). Significantly elevated concentrations of six phthalate 
metabolites were observed in African American women compared to Caucasian women 
(p < 0 .005). In addition, concentrations of MEOHP, MEHHP, and ∑DEHP were higher 
in African Americans than in Caucasians, though the differences were not statistically 
significant. College-educated women had the lowest phthalate concentrations, and this 
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difference was significant for MBP, MBzP, MiBP, MEP, and MMP (p < 0.005). Women 
who were married or living as married had significantly lower phthalate levels than 
unmarried women (p < 0.05), with the exception of MEHP. Lastly, women whose annual 
household income was less than $25,000 or who did not know their household income 
exhibited the highest phthalate concentrations, while women with incomes of $65,000 or 
more displayed the lowest phthalate levels (p < 0.05 for MBP, MBzP, MiBP, MEP, and 
MMP). 
Multivariate Analysis 
Urinary phthalate metabolite concentrations in the overall population of pregnant 
women showed significant differences after controlling for age, BMI, race, education, 
marital status, and household income (Table 2.7). After adjusting for age, BMI, 
education, marital status, and household income, race remained significantly associated 
with concentrations of MBzP, MiBP, MEP, and MMP (p < 0.05), with African 
Americans displaying higher phthalate levels than Caucasians. The greatest difference 
was seen with MEP, which was 62% higher in African Americans than in Caucasians 
(Figure 2.1).   
After adjusting for age, race, education, marital status, and household income, 
BMI remained positively associated with concentrations of MBP, MBzP, and MiBP (p < 
0.05). Maternal education level was inversely correlated with MBP, MiBP, and MEP 
concentrations (p < 0.05). Concentrations of MEP decreased by 21% for every one-level 
increase in education (from less than high school, to high school, to some college, to a 
college education or more). Age and marital status were significantly associated with 
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concentrations of MBP (p < 0.05), with a one-year increase in age resulting in a 3% 
increase, and being single versus married resulting in a 27% increase in MBP, controlling 
for other factors. Household income was significantly associated with MBP and MBzP (p 
< 0.05), with women making over $65,000 per year having lower concentrations than 
women making less than $25,000 per year (p < 0.05 for MBP, MBzP).  
When stratified by race, significant predictors of phthalate exposure varied from 
those seen in the overall population (Tables 2.8 and 2.9). The multivariate analysis of 
African American women only is presented in Table 2.8. Maternal education was a 
stronger predictor of phthalate exposure for African American women than it was for the 
overall population, with increasing educational attainment resulting in significantly 
reduced concentrations of four phthalate metabolites (MBP, MBzP, MiBP, and MEP; p < 
0.05; Figure 2.2). Marital status was no longer significantly associated with MBP 
concentrations, and the significant association between household income and MBzP 
disappeared when considering on African American women (Figure 2.3 and 2.4). There 
were no associations between marital status and phthalates for African American women; 
conversely, marital status was the only predictor of phthalate exposure for Caucasian 
women, with married women having significantly higher concentrations of MBP, 
MEOHP, MiBP, and MMP (p < 0.05) than single women (Table 2.9 & Figure 2.3). 
2.4 Discussion 
In this cross-sectional study of 378 pregnant women, we detected two phthalate 
metabolites in all participants and all other metabolites in at least 93% of subjects. We 
identified several sociocultural characteristics that were associated with above average 
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phthalate concentrations, with race being the most influential. After stratifying by race, 
age, BMI, education, and income were significantly associated with phthalate 
concentrations in African American women, while only marital status was significantly 
associated with phthalate concentrations in Caucasian women. 
Participants in this study were generally younger and more racially diverse than 
pregnant women in similar studies (Suzuki et al. 2012, Bustamante-Montes et al. 2013, 
Swan et al. 2015). Phthalate exposure in our study population was ubiquitous, supporting 
findings from similar exposure assessments that have detected phthalates in 98 to 100% 
of pregnant women both nationally (Just et al. 2010, Woodruff et al. 2011, Cantonwine et 
al. 2016) and internationally (Casas et al. 2011, Lin et al. 2011, Enke et al. 2013). 
Similar to NHANES, the high concentrations of MEP found in our study likely reflect the 
frequent use of phthalate-containing PCPs (Parlett et al. 2013). 
Relative to similar studies conducted in the U.S., phthalate concentrations 
observed in our study population were slightly higher than those reported for The Infant 
Development and the Environment Study (Swan et al. 2015), and were also higher than 
reported values for all U.S. females from 2011 to 2012 (CDC 2017). Concentrations of 
phthalates reported here were generally lower than those in pregnant women from Spain 
and Taiwan (Lin et al. 2011, Valvi et al. 2015), but were similar to concentrations 
reported in pregnant women in Germany (Enke et al. 2013) and Denmark (Jensen et al. 
2016). When considering these trends, it is important to remember that phthalate 
concentrations can be difficult to compare among different studies due to variations in 
extraction, analytical, and urine dilution adjustment methods. 
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Several studies suggest that exposure to certain phthalates (benzyl butyl phthalate 
[BBzP], DBP, and DEHP) has decreased over the past decade following implementation 
of government regulations and voluntary removal, while exposure to others (diisononyl 
phthalate, diisobutyl phthalate) is increasing (Silva et al. 2013, Zota et al. 2014, Calafat 
et al. 2015). In this study, concentrations of all phthalate metabolites except MEHP were 
higher in 2011 and 2013 than in 2012 and 2014, although the differences were not 
statistically significant. MEHP concentrations were significantly higher in 2011 than in 
any subsequent year (p < 0.001, data not shown), indicating a potential decrease in 
exposure to its parent compound DEHP; however, the other DEHP metabolites measured 
here did not corroborate this trend. Additionally, we did not identify any seasonal 
patterns of phthalate exposure. 
Phthalate concentrations were significantly associated with several sociocultural 
factors, including age. In the overall adjusted model and in the stratified model for 
African Americans, MBP concentrations were positively associated with age (Figure 
2.5). Previous studies have not shown associations between age and phthalate 
concentration in men (Duty et al. 2005), or in pregnant Spanish women (Valvi et al. 
2015). There were no significant associations between age and phthalates in the 
Caucasian-stratified model. 
After adjusting for other variables, there were significant positive associations 
between BMI and MBP, MBzP, and MiBP. These associations also remained significant 
for African Americans in the race-stratified model (Figure 2.6). Several previous studies 
corroborate this relationship between BMI and phthalate concentrations (Stahlhut et al. 
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2007, Peck et al. 2010, Buser et al. 2014, Valvi et al. 2015, Yaghjyan et al. 2015), 
including a study of pregnant women in which nine phthalate metabolites exhibited a 
positive correlation with BMI (Wolff et al. 2008). Obesity disproportionately affects 
minorities and those of lower income (Mitchell et al. 2011), which could explain why 
BMI is significantly associated with phthalate concentrations in African Americans but 
not in Caucasians. 
The potential for phthalates to act as obesogens is a research area of growing 
interest that could potentially explain our findings of a positive association between BMI 
and phthalate concentrations. Several in vitro (Feige et al. 2007, Sargis et al. 2010) and in 
vivo studies (Hao et al. 2012) attribute obesogen activity to the interaction of phthalates 
with hormone receptors, leading to disrupted metabolism and increased adipogenesis. 
Specifically, phthalates can bind to peroxisome proliferator-activated receptors alpha and 
gamma, which regulate glucose metabolism and adipocyte activity (Grun et al. 2007, 
Casals-Casas et al. 2008, Desvergne et al. 2009). Epidemiological studies have found that 
urinary levels of some phthalates were associated with the incidence of diabetes among 
women (James-Todd et al. 2012b) and faster weight gain over a period of ten years (Song 
et al. 2014). Additionally, heavier individuals or pregnant women may have greater 
phthalate concentrations due to increased dietary consumption, indoor exposures, 
medication, and personal care product use.  
Race was strongly associated with phthalate concentrations in our population. 
Phthalate concentrations for all metabolites except MEHHP, MEOHP, and ∑DEHP were 
significantly higher in African American women than in Caucasian women. After 
38 
 
controlling for all other variables, race remained significantly associated with 
concentrations of four metabolites (MBzP, MiBP, MEP, and MMP). Several previous 
studies have also detected elevated phthalate concentrations in minorities. From 1999 to 
2000, non-Hispanic black men and women in the U.S. had significantly higher MEP 
concentrations than did Mexican Americans or non-Hispanic whites (Silva et al. 2004a). 
Non-white women of reproductive age in the U.S. from 2001 to 2008 had higher 
concentrations of MBP, MiBP, MBzP, and MEP, but not DEHP metabolites (Kobrosly et 
al. 2012). A third study conducted from 2001 to 2008 found that African American men 
and women aged 12 and up had higher levels of MEP, MBP, MiBP, MBzP, and ∑DEHP 
than whites or Mexican-Americans (Huang et al. 2014). Our results support findings of 
higher phthalate concentrations in African Americans compared to Caucasians, and 
provide evidence for a significant racial disparity in phthalate exposure in the Southeast 
U.S. 
Genetic polymorphisms can contribute to ethnic variations in phase I metabolism 
enzymes (Guillemette 2003, McGraw et al. 2012), providing one potential explanation 
for racial disparities of phthalate concentrations. African Americans may also be subject 
to higher personal care product or dietary phthalate exposures. Several studies have found 
that African American women use more hair products than Caucasians, and that many of 
these hair products contain hormonally active chemicals (Tiwary 1997, Li et al. 2002, 
James-Todd et al. 2012a, Wise et al. 2012). Additionally, a greater proportion of African 
American women compared to white and Mexican American women report use of 
vaginal douches, resulting in significantly higher MEP exposure (Branch et al. 2015). 
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African Americans also generally consume more highly processed foods and fast food 
than Caucasians, which are substantial sources of phthalate exposure (Neff et al. 2009, 
Zota et al. 2016). 
In the regression models stratified by race, education and income were 
significantly associated with phthalate concentrations in African Americans only. In 
contrast, marital status was the only variable that was significantly associated with 
phthalate concentration in Caucasian women, and no phthalates were associated with 
marital status in African American women. Our results suggest that concentrations of 
phthalates are likely to increase in single Caucasian women by 79% for MBP, 64% for 
MMP, 46% for MiBP, and 39% for MEOHP, relative to married Caucasian women 
(Figure 2.3). Low and high molecular weight phthalates were significantly associated 
with marital status, suggesting that single women are exposed to higher levels of 
phthalates through the use of more PCPs and the consumption of more processed foods; 
both are practices associated with a more social lifestyle. However, marital status was not 
significantly associated with concentrations of MEP, a metabolite most commonly 
associated with PCP use. Ultimately, the explanation for this association remains unclear 
and merits further investigation. To our knowledge, this is the first description of an 
association between marital status and phthalate concentration. 
The only metabolites to maintain significant inverse associations with income in 
the fully adjusted model were MBP and MBzP, with women making less than $65,000 
per year or women who did not know their household income having higher 
concentrations than those making over $65,000 per year. In the race-stratified analysis, 
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income was a significant predictor of phthalate exposure in African Americans only. 
African American women who were unaware of their annual household income had 87% 
higher MBP concentrations and 80% higher MEOHP concentrations than African 
American women making over $65,000 per year. Additionally, African American women 
with household incomes of less than $25,000 had 80% higher MBP concentrations than 
African American women with household incomes of greater than $65,000. These results 
could be influenced by the fact that only 2.9% of African American women in our study 
population reported an income of over $65,000 per year. Income was not associated with 
phthalate exposure in Caucasian women. 
Results from studies examining associations between SES and phthalate 
concentrations have varied, with some agreeing with our findings of an inverse 
association, and others showing a positive association (Koo et al. 2002, Ye et al. 2008, 
Adibi et al. 2009, Kobrosly et al. 2012, Tyrrell et al. 2013, Valvi et al. 2015). In four 
epidemiological studies, positive associations were found between social class, education, 
income, and SES and phthalate exposure (Ye et al. 2008, Casas et al. 2011, Kobrosly et 
al. 2012, Tyrrell et al. 2013). These findings, in addition to ours, suggest that associations 
between SES and phthalate concentrations are highly variable and dependent on the 
metabolites and population in question.  
Several limitations should be considered when interpreting these results. First, all 
analyses are based on phthalate measurements from a single urine sample taken in the 
second trimester of pregnancy. Phthalates are rapidly metabolized and excreted from the 
body and we were not able to control for sampling time or exposures prior to sampling. 
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However, two studies have shown that a spot urine sample can be representative of 
phthalate exposure over a couple of days (Hoppin et al. 2002) or several months (Hauser 
et al. 2004). Second, we assume that phthalates have similar pharmacokinetic properties 
in all individuals, and that excretion rates do not vary. We know this is unlikely, but have 
attempted to minimize variability by correcting for urine concentration with specific 
gravity measurements and performing race-stratified multiple regressions. Lastly, we 
may be missing other potentially important predictive variables, such as dietary and PCP 
use habits. Future work will incorporate dietary information and additional sampling time 
points into the analysis. Major strengths of this study are its racially diverse population 
and relatively large sample size (n = 378). Our cohort consisted of 49% African 
American and 51% Caucasian women, providing a unique opportunity to examine racial 
disparities in phthalate concentrations.  
We have identified several potential risk factors that predict women with above 
average phthalate concentrations. Prevalent phthalate exposure in pregnant women is 
concerning, as the adverse health effects of these chemicals on reproductive development 
are well known. Therefore, efforts should be taken to educate pregnant women, 
especially pregnant women shown to be at risk for high exposure, about sources of 
phthalate exposure and exposure reduction strategies. 
2.5 Conclusions 
In summary, we present phthalate concentrations in a racially diverse population 
of pregnant women in Charleston, SC. We found that phthalate concentrations were 
higher in women who were African American, less educated, single, had higher BMI, 
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and/or low household income. Predictors of phthalate exposure varied by race, 




Table 2.1. HPLC gradient program. Flow rate: 0.35 mL/min; mobile phase A: 1 mL 








STEP Time (min) A (%) B (%) 
0 (Equilibration) 10 25 75 
1 10 33 67 
2 16 40 60 
3 33 45 55 
4 (Flush) 35 100 0 
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Table 2.2. Phthalate metabolites and their native and labeled precursor and product ion 
transitions, and retention times (RT). a Labeled MBP was used as an internal standard for 
MiBP. 
 
 Precursor/product ions (m/z)  
Analyte Native Labeled RT (min) 
MMP 179/77 183/79 3.3 
MEP 193.1/77 197/79 4.9 
MBP 221/77 225/79 12.6 
MiBP 221/77 225/79 a 12.1 
MBzP 255/183 259/186 16.9 
MEHP 277/134 281/137 29.1 
MEOHP 291/121.1 295/124 14.1 





Table 2.3. Distributions of clinical and sociocultural characteristics overall and by race. 
Continuous variables are reported as median (interquartile range) and categorical 
variables are reported as n (%). Characters represent missing observations: a n = 1, b n = 
3, c n = 2, d n = 4, e n = 19, f n = 21, g n = 20, h n = 24. 
 
Clinical and demographic 
variables 
Overall 
(n = 378) 
African 
American 
(n = 186) 
Caucasian 
(n = 192) 
Age, years a 27.0 (8) 24.0 (8) 29.0 (7.5) 
BMI b 27.2 (8.5) 29.4 (9.8) 26.3 (6.4) 
Nulliparous c 153 (40.4) 60 (32.1) 93 (48.9) 
Ever smoker d 45 (11.8) 24 (12.9) 21 (11.1) 
Used medication during 
pregnancy e 144 (40.0) 67 (38.1) 77 (41.8) 
Used prenatal vitamins 
during pregnancy f 316 (88.3) 148 (84.6) 168 (91.8) 
Used contraception before 
pregnancy f 69 (19.3) 26 (14.9) 43 (23.4) 
Married or living as 
married g 197 (54.9) 44 (25.1) 153 (83.2) 
Education f 



















Household income h 
< $25,000 






























































Table 2.4. Limits of detection, detection frequency, and concentrations of urinary phthalate metabolites (ng/mL) during 
pregnancy in this study (n = 378) and in NHANES females from 2011 to 2012 (n = 1229). LOD = limit of detection; DF = 
detection frequency; GM = geometric mean; NHANES = National Health and Nutrition Examination Survey.  
a values adjusted for specific gravity, b values not adjusted for specific gravity, c Centers for Disease Control (CDC) Fourth 
Report Updated, unadjusted values for females aged 6+ 2011-2012, d Not calculated: proportion of results below limit of 









DF (%) SG-adjusted GM a 
(95% CI) 
Unadjusted GM b  
(95% CI)  
NHANES ‘11-‘12 c GM 
(95% CI)  
DEHP MEHP 0.35 95.8 3.13 (2.85–3.45) 2.65 (2.36–2.99) 1.24 (1.14–1.34) 
DEHP MEOHP 0.10 99.7 5.92 (5.48–6.42) 5.02 (4.50–5.62) 7.20 (6.77–7.66) 
DEHP MEHHP 0.10 100 7.49 (6.92–8.09) 6.34 (5.70–7.10) 4.71 (4.39–5.07) 
DBP MiBP 0.17 100 11.3 (10.4–12.3) 9.57 (8.44–10.8) 5.52 (4.95–6.15) 
DBP MBP 0.95 98.4 16.1 (14.8–17.6) 13.7 (12.1–15.5) 7.14 (6.05–8.41) 
BBzP MBzP 0.10 98.4 11.2 (9.83–12.8) 9.47 (8.06–11.1) 4.27 (3.81–4.77) 
DMP MMP 0.34 93.7 2.27 (2.01–2.54) 1.92 (1.66–2.23) d 






Table 2.5. Pearson’s correlation coefficients among phthalate metabolites (n = 378).  






MBZP MEHP MEOHP MEHHP ∑DEHP  MiBP MEP MMP 
MBP - 0.66 0.27 0.42 0.38 0.38 0.70 0.40 0.47 
MBzP  - 0.23 0.30 0.26 0.28 0.51 0.33 0.35 
MEHP   - 0.71 0.73 0.84 0.17 0.11 0.21 
MEOHP    - 0.97 0.96 0.32 0.18 0.27 
MEHHP     - 0.97 0.30 0.15 0.26 
∑DEHP      - 0.28 0.15 0.26 
MiBP       - 0.38 0.41 
MEP        - 0.26 





Table 2.6. Univariate associations between clinical and sociocultural factors and urinary phthalate metabolites a. ref = reference 
group; a Specific gravity-corrected, natural log-transformed phthalate values in ng/mL, b Pearson correlation coefficient, c 
Student's t-test, d one-way ANOVA, e geometric mean (standard deviation), f  Molar sum of DEHP metabolites (MEHP, 
MEOHP, MEHHP) in nmol/L ; * p < 0.05 relative to reference group.  
 
Demographic 
factors n MBP MBzP MEHP MEOHP MEHHP ∑DEHP 
f MiBP MEP MMP 
Age b 378 -0.09 -0.24* -0.13* -0.08 -0.07 -0.10 -0.14* -0.13* -0.10 
BMI b 376 0.30* 0.27* 0.03 0.12* 0.11* 0.10 0.22* 0.14* 0.11* 
Race c, e           
African 


































Education d, e           
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Table 2.7.  Multiple linear regression associations between clinical and sociocultural factors with maternal urinary phthalate 
metabolites a in the overall population (n = 378). a Specific gravity-corrected, log-transformed values, b Model mutually adjusts 
for age, BMI, race, education, marital status, and household income, c Molar sum of DEHP metabolites (MEHP, MEOHP, 
MEHHP) in nmol/L; * p < 0.05. 
  Overall βadjusted b (95% CI) 


































































































































































































































Table 2.8. Multiple linear regression associations between clinical and sociocultural factors with maternal urinary phthalate 
metabolites a in African Americans only (n = 186). a Specific gravity-corrected, log-transformed values, b Model mutually 
adjusts for maternal age, BMI, education, marital status, and household income, c Molar sum of DEHP metabolites (MEHP, 
MEOHP,  MEHHP) in nmol/L; * p < 0.05. 
 
  βadjusted b (95% CI) for African Americans 







































































































































































































Table 2.9.  Multiple linear regression associations between clinical and sociocultural factors with maternal urinary phthalate 
metabolites a in Caucasians only (n = 192). a Specific gravity-corrected, log-transformed values, b Model mutually adjusts for 
maternal age, BMI, education, marital status, and household income, c Molar sum of DEHP metabolites (MEHP, MEOHP, 
MEHHP) in nmol/L; * p < 0.05. 
 
  βadjusted b (95% CI) for Caucasians 










































































































































































































Figure 2.1. Percent difference in phthalate concentrations and 95% confidence intervals 
for pregnant African American (n = 186) versus Caucasian (n = 192) women. The model 
mutually adjusts for maternal age, BMI, education, marital status, and household income. 
Phthalate concentrations have been specific gravity-corrected and log-transformed.* p < 
























































Figure 2.2. Percent difference in phthalate concentration and 95% confidence intervals 
for a one-unit increase in education in African American (n = 186) and Caucasian (n = 
192) women. The model mutually adjusts for maternal age, BMI, race, marital status, and 
household income. Phthalate metabolite concentrations have been specific gravity-
corrected and log-transformed. * p < 0.05 for a significant decrease in phthalate 































































Figure 2.3. Percent difference in phthalate concentration and 95% confidence intervals 
for unmarried versus married African American (n = 186) and Caucasian (n = 192) 
women. The model mutually adjusts for maternal age, BMI, race, education, and 
household income. Phthalate metabolite concentrations have been specific gravity-
corrected and log-transformed. * p < 0.05 for significantly increased phthalate metabolite 





















































Figure 2.4. Percent difference in phthalate concentration and 95% confidence intervals 
for African American (n = 186) and Caucasian (n = 192) women making less than 
$25,000 per year compared to women making more than $65,000 per year. The model 
mutually adjusts for maternal age, BMI, race, education, and marital status. Phthalate 
metabolite concentrations have been specific gravity-corrected and log-transformed. * p 
< 0.05 for significantly increased phthalate metabolite concentrations in women making 























































Figure 2.5. Percent difference in phthalate concentration and 95% confidence intervals 
for a five-year increase in age in African American (n = 186) and Caucasian (n = 192) 
women. The model mutually adjusts for maternal BMI, race, education, marital status, 
and household income. Phthalate metabolite concentrations have been specific gravity-
corrected and log-transformed.* p < 0.05 for a significant increase in phthalate metabolite 



















































Figure 2.6. Percent difference in phthalate concentration and 95% confidence intervals 
for a one-unit increase in BMI in African American (n = 186) and Caucasian (n = 192) 
women. The model mutually adjusts for maternal age, race, education, marital status, and 
household income. Phthalate metabolite concentrations have been specific gravity-
corrected and log-transformed.* p < 0.05 for a significant increase in phthalate metabolite 


















































Chapter 3. Influence of race on prenatal phthalate exposure and anogenital 
measurements among boys and girls  
3.1 Introduction 
Phthalates are a group of industrial chemicals used as plasticizers and solvents 
that are likely to act as developmental reproductive toxicants in males (Kay et al. 2014) 
and females (Kay et al. 2013). Humans are exposed to high molecular weight phthalates 
such as diethylhexyl phthalate (DEHP) primarily through diet, as these phthalates are 
major components of polyvinyl chloride used in food packaging and processing (Schecter 
et al. 2013). Low molecular weight phthalates such as diethyl phthalate (DEP) are often 
used in personal care products, cosmetics, and pharmaceuticals (ATSDR 2002, 
Hernández-Díaz et al. 2013, Parlett et al. 2013). Despite rapid metabolism of phthalates 
into monoester metabolites and subsequent excretion, phthalate exposure is ubiquitous. 
Nearly 100% of pregnant women in the U.S. have detectable urinary levels of multiple 
phthalate metabolites, raising concern for fetal exposure during critical periods of genital 
development (Woodruff et al. 2011). 
Anogenital distance (AGD), the distance from the anus to the genitalia, is a 
sexually dimorphic trait that serves as an indicator of prenatal androgen exposure in 
rodents and humans (Thankamony et al. 2016). Adverse developmental outcomes 
associated with shortened AGD, an antiandrogenic effect, include hypospadias and 
cryptorchidism (Hsieh et al. 2008, Hsieh et al. 2012, Thankamony et al. 2014), poor 
sperm quality (Mendiola et al. 2011, Eisenberg et al. 2012), reduced testosterone levels 
(Eisenberg et al. 2012), and diminished fertility (Mendiola et al. 2015).  
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Certain phthalate metabolites are endocrine disrupting compounds (EDCs) that 
act as antiandrogens by disrupting Sertoli and Leydig cell development and by interfering 
with androgen steroidogenesis (Mylchreest et al. 2002). In rodent models, conservative 
doses of phthalates administered to pregnant dams resulted in male offspring with 
reproductive abnormalities, including shortened (feminized) AGDs (Gray et al. 2000, 
Foster 2006). Reproductive tract abnormalities are also reported in female pups following 
gestational phthalate exposure (Grande et al. 2007, Hotchkiss et al. 2007, Hannas et al. 
2013), and a longer AGD has been associated with the presence of multifollicular ovaries 
resulting from increased androgen exposure in human females (Mendiola et al. 2012). 
Several prior studies have described relationships between prenatal phthalate 
exposures and AGD in humans, but results vary. In a seminal investigation, Swan and 
colleagues (2005) reported inverse associations between maternal urinary monoethyl 
phthalate (MEP), mono-n-butyl phthalate (MBP), monobenzyl phthalate (MBzP), and 
monoisobutyl phthalate (MiBP) with body weight-standardized AGD. Urinary 
concentrations of MEP, MBP, and three DEHP metabolites (mono-2-ethylhexyl phthalate 
[MEHP], mono-2-ethyl-5-oxohexyl phthalate [MEOHP], and mono-2-ethyl-5-
hydroxyhexyl phthalate [MEHHP]) were inversely related to male AGD in an expanded 
cohort (Swan 2008). This inverse association between DEHP metabolites and AGD was 
later replicated in a different cohort by Swan and colleagues (2015). Inverse associations 
between MEHP (but not MEOHP or MEHHP) and AGD have also been described in 
Japanese infants (Suzuki et al. 2012), and total phthalate exposure was found to be 
inversely associated with AGD in Mexican infants (Bustamante-Montes et al. 2013). 
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Another large study found modest inverse associations between metabolites of di-
isononyl phthalate (DiNP) and AGD, but results were not statistically significant for 
MEHP (Bornehag et al. 2014). Two additional studies have failed to identify associations 
between phthalate exposure and AGD in boys (Huang et al. 2009, Jensen et al. 2016).  
Associations between prenatal phthalate exposure and AGD measurements in 
females have been studied far less than for males. Animal studies have not shown 
alterations in female AGD following prenatal phthalate exposure, and two human studies 
reported no associations (Swan 2008, Swan et al. 2015). In contrast, a third human study 
reported an inverse association between MBP from amniotic fluid and body weight-
standardized AGD in female infants (Huang et al. 2009).  
Despite the growing interest in AGD as an indicator of gestational exposure to 
EDCs, no previous study has analyzed the impact of race on the relationship with 
prenatal phthalate exposures. Endogenous gestational androgens appear to be higher in 
African Americans compared to Caucasians, inclusive of the genitourinary 
developmental window, which may modify associations with phthalates (Henderson et al. 
1988, Potischman et al. 2005, Faupel-Badger et al. 2011). Therefore, the aim of our study 
was to explore associations between prenatal phthalate exposure and AGD measures in a 
racially diverse population of male and female newborns. We hypothesized there would 
be an inverse association between urinary phthalate metabolites and AGD. We also 




3.2 Materials and Methods 
Chemical Reagents 
 Phthalate metabolites, their isotope-labeled internal standards, and 13C4-4-
methylumbelliferone (>99.9%) were purchased from Cambridge Isotope Laboratories, 
Inc. (Andover, MA, USA).  4-methylumbelliferone (4-MeUmb) and its glucuronide were 
purchased from Sigma Aldrich Laboratories, Inc. (St.Louis, MO, USA). Acetonitrile, 
water (HPLC grade), and ethyl acetate were purchased from Honeywell Burdick and 
Jackson (Morris Plains, NJ, USA). Ammonium acetate, acetic acid (98% min.), and 
monosodium phosphate monohydrate anhydrous were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA). Phosphoric acid (85%) and formic acid (98% min.) 
were purchased from EMD Millipore (Billerica, MA, USA). β-glucuronidase 
(Escherichia coli-K12) was purchased from Roche Biomedical (Mannheim, Germany). 
All chemicals and reagents were used without further purification. 
 
Study Population 
Women from the Charleston, South Carolina metropolitan area who planned to 
deliver at the Medical University of South Carolina (MUSC) between 2011 and 2014 
were recruited to participate in this study (n=407). Women at least 18 years of age with 
uncomplicated singleton pregnancies dated by first trimester ultrasound were eligible.  
Between 18 and 22 (median = 20) completed weeks of gestation, participants 
completed a study questionnaire and provided a urine specimen for analysis (n = 391). A 
subsample of women provided a second urine specimen between 24 and 32 weeks’ 
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gestation (n = 219). Following collection of urine specimens into sterile glass jars, 
specific gravity was determined at room temperature (Boeniger et al. 1993) using a 
handheld refractometer (Atago U.S.A., Inc., Bellevue, Washington, USA), and urine was 
distributed into 1 mL aliquots and frozen at -20°C until analysis. The institutional review 
board of MUSC approved this study and all survey protocols, and all participants signed 
informed consent prior to enrollment.  
 
Anogenital Distance  
Two AGD metrics were obtained on all male (n = 171) and female (n = 128) 
infants (Figure 3.1) born to African American and Caucasian participants with urine 
specimens, within 24 hours of birth according to methods described in detail elsewhere 
(Sathyanarayana et al. 2010). In brief, measurements were made by a single observer in 
triplicate and averaged, using calipers with the infant lying on his or her back at the edge 
of a bed or other flat surface with legs in the frog position. In males, APD was measured 
as the distance from the anterior margin of the anus to the anterior base of the penis 
where the penile shaft skin meets the suprapubic bone, and ASD was measured from the 
anterior margin of the anus to the base of the scrotum where the skin changes from 
smooth to rugated (Figure 3.1). In females, measurements were made from the anterior 
margin of the anus to the base of the clitoral hood (ACD) and to the posterior 




Sample Preparation for Urinary Phthalate Analysis  
Urine samples were transferred to the Hollings Marine Laboratory (Charleston, 
South Carolina) for analysis of eight phthalate metabolites, including monomethyl 
phthalate (MMP), MEP, MBP, MiBP, MBzP, MEHP, MEOHP, and MEHHP. Extraction 
and analysis methods were based on those previously developed by the U.S. Centers for 
Disease Control and Prevention (CDC), and are described in detail elsewhere (Silva et al. 
2004b). 
Stock solutions of phthalate metabolites, 4-MeUmb, and isotopically-labeled 
metabolites and 4-MeUmb were prepared in Millipore water and stored at 4°C in Teflon-
capped glass bottles. The calibration standards, containing native and isotopically-labeled 
phthalate metabolites and 4-MeUmb were prepared in 10% aqueous acetonitrile from 
stock solutions to create ten unique standard solutions and stored at 4°C in Teflon-capped 
glass tubes until use. A standard solution of 4-MeUmb glucuronide (2 μg/mL) was 
prepared in water and added to all urine samples. The 4-MeUmb/13C4 4-MeUmb peak 
area ratio was monitored to check the extent of the deconjugation reaction with β-
glucuronidase. Quality Control (QC) materials were prepared from a urine pool obtained 
from multiple anonymous donors and was enriched with native phthalate metabolites to 
resemble an ‘average’ concentration.  
Urine (1 mL) was thawed, vortex-mixed, and spiked with the internal standard 
containing a mixture of isotopically-labeled analytes (50 μL), 2 μg/mL 4-MeUmb 
glucuronide solution (25 μL), and 2% β-glucuronidase in ammonium acetate buffer (255 
μL, pH 6.5/1M). The sample was incubated at 37 °C for 90 min. to deconjugate the 
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glucuronidated phthalate metabolites. The urine sample was then placed on the 
RapidTrace Station (Zymark Corporation, Hopkinton, MA, USA) for the automated solid 
phase extraction procedure. The solvent lines were purged with methanol before each 
extraction. Polymeric sorbent-filled cartridges (60 mg, 3 mL; Bond Elut NEXUS, Agilent 
Technologies, Santa Clara, CA, USA) were conditioned with 1 mL acetonitrile followed 
by 1 mL pH 2 phosphate buffer (0.14 M NaH2PO4 in 0.85% H3PO4) at 1 mL/min. Urine 
samples were loaded onto the cartridge at 1 mL/min. The column was then rinsed with 2 
mL of 0.1 M formic acid followed by 1 mL of water. Cartridges were dried with air for 
0.5 min. Analytes were eluted with 1 mL acetonitrile followed by 1 mL ethyl acetate at 1 
mL/min. The eluates were transferred to a TurboVap evaporator (Zymark Corporation, 
Hopkinton, MA, USA) and evaporated to dryness at 55°C under a stream of dry nitrogen. 
The residue was resuspended in 200 μL of Millipore water for analysis. 
 
Instrumental Analysis of Phthalate Metabolites 
The analysis was performed using an Agilent 1100 Series liquid chromatography 
system (Santa Clara, CA, USA) coupled to an API 4000 triple quadrupole mass 
spectrometer (Applied Biosystems/MDS Sciex, Framingham, MA, USA) with 
electrospray ionization interface. The system was controlled by Analyst software, version 
1.5.2 (Sciex, Framingham, MA, USA). The autosampler tray was set to 10 °C, and 10 μL 
of the deconjugated urine sample was injected using the autosampler with syringe washes 
between injections. Chromatographic resolution was accomplished using a 3 µm, 150 
mm x 2.1 mm Betasil phenyl column (Thermo Fisher Scientific, Waltham, MA, USA), 
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with a solvent gradient from 25% mobile phase A (0.1% acetic acid in acetonitrile) and 
75% mobile phase B (0.1% acetic acid in water) to 100% mobile phase A at a flow rate 
of 0.35 mL/min before reverting back to primary conditions for 10 min. (Table 3.1). The 
mass spectrometers were tuned and optimized for each analyte. Ion transitions were 
monitored for each analyte in multiple reaction monitoring mode (Table 3.2).  
Isotopically-labeled internal standards were used during phthalate analysis along 
with conjugated internal standards to increase precision and accuracy of the 
measurements. Standard QC and reagent blank samples were included in each analytical 
batch along with participant samples. A batch was re-run if any one QC measurement fell 
outside the 99% confidence interval or if two consecutive QC samples fell outside of the 
95% confidence interval. Standard urine reference material SRM 3673 (Organic 
Contaminants in Non-Smokers) was regularly analyzed alongside participant samples and 
we compared measured phthalate values to the certified values. In addition to analyzing 
eight individual phthalate metabolites, molar sums of the three measured DEHP 
metabolites were also calculated: ∑DEHP = (MEHP*(1/278)) + (MEOHP*(1/292) + 
(MEHHP*(1/294)), in nmol/mL. 
 
Statistical Analysis 
Descriptive statistics were estimated for sociodemographic and clinical factors 
overall and by race, and racial differences were assessed by Student’s t-test or Fisher’s 
exact test. Phthalates were natural log transformed after adding a constant to 
accommodate values below zero in order to normalize distributions before analysis. We 
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did not substitute for values measured below limits of detection (LODs), but used 
instrument reported values to avoid bias that has been demonstrated with imputation 
(Schisterman et al. 2006). Specific gravity (SG) was used to adjust for urine dilution 
according to the following formula: Pc = P((1.016 – 1)/(SG – 1)) where Pc is the SG-
corrected phthalate concentration (ng/mL), 1.016 is the mean SG for all participant urine 
samples, and SG is the individual specific gravity of urine 
We assessed bivariate associations among phthalates, covariates, and AGD 
measures by Pearson correlations or one-way analysis of variance (ANOVA) as 
appropriate. To characterize exposure measurement reliability, we calculated intraclass 
correlation coefficients (ICC) among the subset of women with two urine specimens (n = 
219). Further, we calculated coefficients of variation (CV) across three replicate 
measures of AGD to characterize outcome measurement reliability of the two observers 
for every measurement. 
To evaluate the impact of phthalates on AGD measures we first employed linear 
regression models with individual urinary phthalates or their sums as predictors of AGD 
measures in boys and girls, corrected for birth weight (Swan 2008, Sathyanarayana et al. 
2010) standardized to CDC birth weight curves as a covariate (CDC 2001). Phthalates 
were operationalized as continuous variables to maximize sensitivity for detecting modest 
associations and then as tertiles to allow for non-linear associations. For the analysis of 
tertiles of phthalate concentrations, those in the first tertile had the lowest concentrations, 
and those in the third tertile had the highest concentrations. In a second set of linear 
regression models we also adjusted for confounding variables, selected a priori as 
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predictors of phthalate exposure and fetal development in the literature, coupled to 
directed acyclic graphs (Greenland et al. 1999). These variables included maternal age 
(Sathyanarayana et al. 2015, CDC 2017), race (Potischman et al. 2005, CDC 2017), and 
education as a proxy for socioeconomic status (Bryant et al. 2010, Kobrosly et al. 2012), 
and cigarette smoking during the current pregnancy (Duty et al. 2005, Håkonsen et al. 
2014). We also considered an interaction term between race and phthalates in a third set 
of regression models. Finally, we conducted the analysis stratified by race. We 
implemented a Markov chain Monte Carlo multiple imputation procedure, with 10 
imputed data sets, to accommodate missing values for some covariates (Horton et al. 
2007). Missing values varied by study endpoint but did not exceed 9% of education 
values, 0.02% for cigarette smoking, and 1% for birthweight percentile. We also repeated 
the analysis using a complete-case approach. As a sensitivity analysis for all regression 
models, we excluded influential observations with Dfbeta ≥ |1.00| and repeated the 
analysis (Kleinbaum et al. 1998). 
The statistical analysis was conducted using SAS v.9.4 (SAS Institute Inc., Cary, 
NC, USA). Statistical significance was set at p < 0.05 for main effects and at p < 0.10 for 
interactions, using two-tailed tests.  
 
3.3 Results 
Univariate and Bivariate Analyses 
Sociodemographic characteristics of the study cohort are presented in Table 3.3. 
Mean age of participants was 27.4 years, and mean body mass index (BMI) was 29.1 
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kg/m2. Nearly 12% of participants reported ongoing smoking or having stopped early in 
gestation. Of 380 enrolled mothers, 193 (50.8%) were Caucasian and 187 (49.2%) were 
African American. Collectively, 32.5% of mothers had a high school diploma or less, 
43.1% finished a college or technical school degree, and 48.9% reported a yearly 
household income of more than $45,000. Caucasian mothers were older, had lower BMIs, 
were more highly educated, and reported higher income than African American mothers 
(p<0.001). Study mothers gave birth to 222 boys and 158 girls.   
Table 3.3 also summarizes AGD measures for the cohort. Average APD and ASD 
measures for boys were 44.5 mm and 22.5 mm, respectively. The APD and ASD 
measurements were similar for African Americans and Caucasians. We detected a 
positive, yet weak correlation between maternal BMI and APD (r = 0.17; p = 0.02). For 
girls, the mean ACD and AFD (33.6 mm and 12.9 mm, respectively) were, as expected, 
shorter than the corresponding measurements in boys. AFD was -0.94 mm shorter in 
Caucasians than in African Americans (p = 0.03). ACD differed according to level of 
maternal education, with shorter measurements observed on girls born to less educated 
mothers (p = 0.02). Intra-observer variation was small with all CVs < 10%; APD = 2.6%, 
ASD = 4.5%, ACD = 2.6%, and AFD = 6.3%. 
The distribution of specific gravity-corrected values for eight urinary phthalate 
monoesters measured in 380 African American and Caucasian study mothers is 
summarized in Table 3.4. More than 95% of values exceeded LODs for the phthalates 
measured, including 100% of MiBP and MEHHP. The only exception was MMP, which 
was detectable in 86.2% of samples. MEP demonstrated the highest average 
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concentration (201 ng/mL), while MEHP was lowest (5.9 ng/mL). Mean molar sums for 
monoester metabolites were 96.1, 206, and 280 nmol/L for ∑DEHP, ∑DBP, and ∑BzBP, 
respectively. Urinary phthalate metabolites displayed significant and weak to strong 
positive correlations with each other (p < 0.05), ranging from r = 0.15 for MEP with 
MEHP to r = 0.98 for MEHHP with MEOHP (Table 3.5). Geometric mean 
concentrations were similar for a subsample of 219 mothers who provided a second urine 
specimen in the third trimester (data not shown), although ICCs were generally low 




Both unadjusted and birth weight-corrected multivariable linear regression models 
identified a significant inverse association between MEHP and APD, accompanied by a 
consistent pattern of inverse associations between all other urinary phthalates and APD, 
albeit without statistical significance (Table 3.6). In contrast, there was a significant 
positive association between ASD and concentrations of MBP, MBzP, ∑DBP, and 
∑BzBP. We detected a similar pattern of positive effect estimates in unadjusted birth 
weight-corrected models, with significant positive, stronger associations for ASD with 
MBP, MiBP, MBzP, ∑DBP, and ∑BzBP. We found analogous patterns of results when 
operationalizing phthalate concentrations as tertiles, including shorter APD with higher 
MBP, MEOHP, MEHHP, and ∑DEHP, as well as longer ASD with higher urinary MBzP 
and ∑DPB (Table 3.7).  
71 
 
We did not detect statistical interactions for APD and ASD when using multiple 
linear regression models incorporating a cross-product term for race and maternal urinary 
phthalates (Table 3.8). However, when stratified by Caucasian and African American 
race, we continued to identify a pattern of inverse associations for phthalates with APD 
that was similar to the unstratified model, although MEHP results were statistically 
significant for only African Americans. We found mixed directions for the effects of 
phthalates on ASD, with significant positive associations for MiBP, ∑DBP, and ∑BzBP 
in Caucasians, and no effects detected among African Americans. Using tertiles of 
phthalate concentrations as predictors, associations with APD were mostly negative for 
exposures in the third tertile as expected, with statistical significance for MBP, MEOHP, 
and MEHHP among Caucasians, and MEOHP among African Americans (Table 3.9). In 
contrast, tertiles of phthalate exposure were not significant predictors of ASD and the 
direction of effects was mixed. 
 
Girls: 
Linear regression models found a significant positive association between MiBP 
and AFD in the unadjusted analysis; however, no significant associations were identified 
for phthalates with ACD or AFD in the covariate-adjusted models (Table 3.10). We 
found no significant associations when operationalizing exposures as tertiles, although 
effects for ACD were mostly inverse, while those for AFD were mixed (data not shown).  
In multiple linear regression models that incorporated a cross-product term 
between race and phthalates, we detected statistically significant interactions influencing 
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ACD outcomes (Table 3.11). The impacts of MBP (p = 0.06), MEP (p = 0.01), ∑DBP (p 
= 0.04), and ∑BzBP (p = 0.09) on ACD varied by race. Race stratified, covariate-
adjusted linear regression models for ACD indicated a positive association with MBP 
(Figure 3.2) among Caucasians (β = 1.24; 95% CI = -1.07, 3.54) and an inverse 
association among African Americans (β = -0.79; 95% CI = -2.10, 0.52). We detected 
similar patterns among Caucasians and African Americans for MEP, ∑DBP, and ∑BzBP 
(Figure 3.2). Using tertiles of phthalates stratified by race, we detected statistically 
significant associations stratified by race for tertiles of urinary phthalates and female 
AGDs (Table 3.12), in which the third tertile of MEP was associated with shorter ACD in 
African Americans only (β = -3.01; 95% CI = -5.36, -0.65; p = 0.01), and the 2nd tertile 
of MMP was associated with longer AFD in Caucasians only (β = 1.84; 95% CI = 0.42, 
3.25; p = 0.01).  
 
3.4 Discussion 
In this prospective study of 380 pregnant African American and Caucasian 
women and their newborns, we found a significant inverse association between second 
trimester gestational MEHP exposure and APD in boys, and we detected significant 
positive associations between prenatal exposure to MBP, MBzP, ∑DBP, and ∑BzBP and 
ASD. In newborn girls, we found no association between prenatal phthalate exposure and 
ACD or AFD overall, but detected significant interactions between phthalate exposure 
and race with respect to ACD. While unexpected given our a priori hypothesis, our 
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results are the first to our knowledge to describe a potential impact of race on 
associations between gestational phthalate exposure and AGD in newborns. 
  Compared to similar studies, mothers in this cohort were generally younger, more 
racially diverse, and less educated. Anogenital measurements reported here were slightly 
smaller than those reported for newborns in The Infant Development and the 
Environment Study (TIDES), a large prior investigation (n = 753) of gestational phthalate 
exposure and AGD measures (Swan et al. 2015); in mm: APD 44.5 vs. 49.7; ASD 22.5 
vs. 24.7; ACD 33.6 vs. 36.6; and AFD 12.9 vs. 16.0. However, smaller AGDs reported 
herein possibly reflect a systematic difference in our approach to AGD measurements 
compared to TIDES, as our AGD measures were comparable to those reported by studies 
from Japan, Taiwan, and Mexico (Huang et al. 2009, Suzuki et al. 2012, Bustamante-
Montes et al. 2013).  
As expected, phthalate exposures in our study population were prevalent, and, in 
fact, higher than those reported in similar studies conducted in the U.S. (Swan 2008, 
Swan et al. 2015). Median values for phthalates without specific gravity correction were 
also higher, respectively, than reported for U.S. women 18-45 years of age between 2011 
and 2014 (CDC 2017), including MBP (14.9 vs. 8.71 ng/mL), MiBP (9.79 vs. 6.13 
ng/mL), MBzP (10.1 vs. 4.64 ng/mL), MEHP (2.76 vs. 1.40 ng/mL), MEOHP (5.78 vs. 
4.71 ng/mL), MEP (43.8 vs. 30.3 ng/mL), and MMP (2.20 vs. 0.80 ng/mL in 2011). 
Concentrations were similar for MEHHP (7.17 vs. 6.89 ng/mL). Importantly, most 
urinary phthalate concentrations were higher among African American women relative to 
Caucasian women in our study.  
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MEHP was the only phthalate metabolite that was significantly and inversely 
associated with APD at birth. However, we also noted consistent weak inverse 
associations between all other measured urinary phthalate metabolites and APD, 
consistent with previous reports suggesting antiandrogenic effects of prenatal phthalate 
exposure (Swan 2008, Suzuki et al. 2012, Bustamante-Montes et al. 2013, Swan et al. 
2015). Only African American males retained a significant inverse association between 
MEHP and APD in the race-stratified model, suggesting potentially stronger 
antiandrogenic effects for MEHP in African Americans.  
In contrast, we detected unexpected significant positive associations between 
MBP, MBzP, ∑DBP, and ∑BzBP with ASD, contradicting findings from previous 
studies that report inverse associations between phthalates and ASD (Suzuki et al. 2012, 
Bustamante-Montes et al. 2013, Bornehag et al. 2014, Swan et al. 2015). These results in 
males were not modified by race, suggesting similar reproductive development impacts 
for gestational phthalate exposure in boys regardless of race. While the contradictory 
ASD results may reflect chance, given the large number of statistical tests conducted 
during this study, it is also possible that reduced scrotal volume paradoxically lengthened 
ASD despite an overall shortened APD. Unfortunately, we did not record scrotal volume 
and are unable to further explore this hypothesis in the current study. Still, associations 
were negative between ASD and MEHP, MEOHP, MEHHP, and ∑DEHP in Caucasians, 
suggesting greater consistency to previous findings for infants born to Caucasian 
mothers. Concentrations of DEHP metabolites are more similar between most 
populations studied than other metabolites, potentially explaining consistent results. For 
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example, the mean concentration of MEHP in our study was 5.9 ng/mL, compared to 
6.04 ng/mL in the TIDES population.  
Significant associations between prenatal phthalate exposure and ACD or AFD 
were not detected, and there was no consistent trend in effect direction across the 
measured phthalates overall. Our results confirm findings from a similar study, which 
also reported inconclusive results for associations between phthalates and female AGD 
(Swan et al. 2015). Whereas substantial evidence exists that in utero androgen exposure 
can modify female anogenital measurements in rodents (McDermott et al. 1978, 
Hotchkiss et al. 2007), Hannas and colleagues (2013) reported that females were two 
times less sensitive to the reproductive effects of a phthalate mixture than males, 
potentially explaining the absence of main effects for girls in this study and others. 
However, MBP, MEP, ∑DBP, and ∑BzBP were associated with longer ACD in girls 
born to Caucasian mothers and a shorter ACD in girls born to African American mothers 
in our study. This might reflect the higher levels of phthalate exposure in African 
Americans, leading to greater antiandrogenic effects and a shorter ACD at birth.  
Other genetic or biological factors could also explain the racial differences in 
ACD outcomes. Several studies have shown that maternal androgens are higher in 
African Americans compared to Caucasians (Potischman et al. 2005, Faupel-Badger et 
al. 2011). Normally, higher androgen exposure would predict a longer (masculinized) 
expected ACD in African Americans. In our results, the shortened ACDs suggest that 
African American females may be more vulnerable to the antiandrogenic effects of 
phthalates than Caucasians. Additionally, estrogen levels are generally higher in African 
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Americans than in Caucasians (Potischman et al. 2005, Rohrmann et al. 2007). Although 
it is unknown how phthalates influence estrogens, this basic biological attribute could 
influence outcomes at the molecular level. Gene polymorphisms of enzymes involved in 
both the steroid hormone pathway and in xenobiotic metabolism also vary by race and 
could contribute to variations in phthalate activity (Guillemette 2003, Catherino et al. 
2013).  
Race did not modify relationships between phthalates and AFD, which may in 
part reflect the higher intra-observer variability for this smaller of the two measurements 
(CV = 6.3%), or distinct developmental processes differentially affected by phthalate 
exposures, androgens, and race. We also found a possible non-linear dose-response 
relationship for AFD with maternal MMP concentrations, in which the effects found in 
the 2nd  tertile of women with average phthalate concentrations were significantly 
different from the least exposed 1st tertile, but the most exposed 3rd tertile were not. This 
non-linear effect may account for the null overall results. Yet as expected, AFD was 
significantly larger in African Americans compared to Caucasians, and so perhaps ACD 
is a more sensitive indicator of gestational phthalate exposure in girls than AFD. Still, in 
an unadjusted comparison there was no difference for ACD by race, possibly reflecting 
the impact of phthalate exposure. Ultimately, it remains unclear why the relationship 
between phthalate exposure and ACD was significantly influenced by race but AFD was 
not. Given the small sample size and multiple comparisons, these results could be 
spurious, meriting a larger future investigation.  
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There are important limitations to this study that should be considered when 
interpreting our results. We collected maternal urine specimens during gestational weeks 
18-22, although reproductive system development largely occurs during gestational 
weeks 7-13 (Sharpe 2006), and sexually dimorphic AGD becomes apparent between 
gestational weeks 11-13 in humans (Fowler et al. 2011). Mistimed specimen collection 
could have biased our results towards the null. In fact, a recent study reported inverse 
associations between DEHP metabolites and AGD only for 1st trimester urine, proposing 
a susceptibility window around weeks 10-12 of gestation (Martino-Andrade et al. 2016). 
Two additional studies also reported inverse associations between 1st trimester prenatal 
phthalate exposure and AGD outcomes (Bornehag et al. 2014, Swan et al. 2015). 
Furthermore, exposure misclassification with bias towards the null was further 
exacerbated by only modest reliability, indicated by low to moderate ICCs calculated for 
urinary phthalate measures over several weeks in a subsample of study participants. 
These ICCs are similar to those reported for urine collected from women without 
pregnancy over one month (Peck et al. 2010), but lower than those reported for urine 
collected from women without pregnancy over two days (Hoppin et al. 2002). This raises 
the possibility that phthalate concentrations captured from spot urine samples in our study 
may not always be representative of an individual’s exposure.   
Another limitation is that we did not measure certain variables that have recently 
been found to alter AGD. Prenatal stress has been associated with longer AGD in females 
and was weakly associated with a shorter AGD in males (Barrett et al. 2013). Higher first 
trimester human chorionic gonadotropin has also been associated with longer AGD in 
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female neonates and a shorter AGD in male neonates, potentially explaining up to 25–
78% of the phthalate-induced variability in AGD (Adibi et al. 2015). In our statistical 
analysis, we corrected for birth weight percentile (z-score) but did not adjust for parity, 
which has also been shown to be associated with shorter male AGD (Barrett et al. 2014). 
Additionally, we were unable to measure all phthalate metabolites of interest, including 
those of the known antiandrogen DINP, the prevalent monocarboxyoctyl phthalate 
(MCOP), and the fourth most common DEHP metabolite, mono-2-ethyl-5-carboxypentyl 
phthalate (MECPP).  
Despite limitations, a major strength of this study is that it is the first to our 
knowledge to investigate the differences in racial responses to prenatal phthalate 
exposure. Previous studies of maternal phthalate exposure and AGD were mostly 
comprised of homogenous Caucasian populations. We enrolled a population that was 
approximately half Caucasian and half African American, allowing us to explore 
potential racial disparities. Additionally, ours is one of few studies to evaluate AGD in a 
large sample of girls. We captured four measures of AGD, with high reliability, and our 
data collection protocol allowed adjustment for a comprehensive set of confounders. We 
used LC-MS/MS to determine a broad panel of urinary phthalates most prevalent in U.S. 
biomonitoring studies, which we operationalized both as continuous and categorical 
predictors with similar results. Finally, the prospective nature of this study with 
gestational exposure assessment is another critical study strength, establishing 





In summary, our results of inverse associations between prenatal phthalate 
exposure and APD are consistent with those previously reported, and our findings are 
also consistent with the few results that have been presented for girls. Our results are 
somewhat discordant to previous human studies showing inverse associations between 
maternal phthalate exposure and ASD in boys. We found a significant inverse association 
between MEHP and APD in newborn boys, yet we identified significant positive 
associations between four maternal urinary phthalates and ASD. Ours is the first study to 
report race as a potential effect modifier for the relationship between four maternal 
urinary phthalate metabolites and ACD in newborn girls, although without a main effect. 
We also detected potential non-linear associations between maternal urinary phthalates 
with AFD by race. Overall, these data suggest that the impact of prenatal phthalate 
exposure on AGD varies by race and sex. These results underscore a need for further 






Table 3.1. HPLC gradient program. Flow rate: 0.35 mL/min; mobile phase A: 1 mL 










STEP Time (min) A (%) B (%) 
0 (Equilibration) 10 25 75 
1 10 33 67 
2 16 40 60 
3 33 45 55 
4 (Flush) 35 100 0 
81 
 
Table 3.2. Phthalate metabolites and their native and labeled precursor and product ion 
transitions, and retention times (RT). a Labeled MBP was used as an internal standard for 
MiBP. 
 
 Precursor/product ions (m/z)  
Analyte Native Labeled RT (min) 
MMP 179/77 183/79 3.3 
MEP 193.1/77 197/79 4.9 
MBP 221/77 225/79 12.6 
MiBP 221/77 225/79 a 12.1 
MBzP 255/183 259/186 16.9 
MEHP 277/134 281/137 29.1 
MEOHP 291/121.1 295/124 14.1 




Table 3.3. Distribution of demographic variables and genital measures in study participants with urinary phthalates measured 
(n = 380). Min, minimum observed value; Max, maximum observed value, SD, standard deviation. a n = 1 missing 
observation, b n = 3 missing observations, c n = 20 missing observations, d n = 118 missing observations, * p = 0.03 using 
Student’s t-test for difference by race. 
 
Demographic Factors n (%) Mean ± SD Min 25th%tile Median 75th%tile Max 
Age (years) 379 a 27.4 ± 5.6 18.0 23.0 27.0 31.0 44.0 
BMI (kg/m2) 377 b 29.1 ± 7.2 17.5 24.0 27.3 32.3 65.1 
Current smoker (%) 44 (11.7) - - - - - - 
Infant sex (%)        
   Male 222 (58.4) - - - - - - 
   Female 158 (41.6) - - - - - - 
Race (%):         
   Caucasian  193 (50.8) - - - - - - 
   African American  187 (49.2) - - - - - - 
Education level (%): c        
   Some high school 40 (11.1) - - - - - - 
   High School 77 (21.4) - - - - - - 
   Some college or technical school 88 (24.4) - - - - - - 
Finished college or technical school 155 (43.1) - - - - - - 
Household Income (%): d        
   Less than $15,000 63 (24.0) - - - - - - 
   $15,000-$45,000 71 (27.1) - - - - - - 
   $45,000-$75,000 52 (19.9) - - - - - - 
   $75,000 and over 76 (29.0) - - - - - - 
Genital measurements (mm)        
  Anopenile distance  171 44.5 ± 5.6 17.9 41.1 44.4 48.1 59.5 
  Anoscrotal distance  171 22.5 ± 4.8 10.4 19.7 22.2 25.5 35.5 
  Anoclitoral distance  128 33.6 ± 4.1 21.4 31.2 33.6 36.2 43.9 





Table 3.4. Distribution of maternal urinary phthalates, in ng/mL (n = 380). ICC, intraclass correlation coefficient; LOD, limit 
of detection; Min, minimum observed value; Max, maximum observed value, SD, standard deviation. a Specific gravity-
corrected in ng/mL, b n = 219 mothers with two urine specimens, c n = 1 missing value, d sum of DEHP metabolites (MEHP, 
MEOHP, MEHHP) in nmol/L, e sum of DBP metabolites (MiBP, MBP) in nmol/L, f sum of BzBP metabolites (MBzP, MBP) 
in nmol/L.   
 
 
Phthalates a Mean ± SD Min 25th%tile Median 75th%tile Max LOD % >LOD ICC b 
MBP 27.5 ± 73.5 1.6 9.3 16.3 28.1 1350 0.95 98.5 0.50 
MiBP 18.3 ± 36.1 1.2 6.7 10.8 19.1 610 0.10 100 0.58 
MBzP  40.0 ± 353 0.01 5.6 11.9 26.4 6870 1.00 98.5 0.68 
MEHP 5.9 ± 13.6 0.3 1.7 3.00 5.30 211 0.17 95.9 0.31 
MEOHP  9.6 ± 27.6 0.3 3.8 5.80 9.00 517 0.34 99.7 0.13 
MEHHP 12.4 ± 32.3 0.9 4.5 7.10 12.2 591 0.10 100 0.12 
MEP c 201 ± 525 2.9 22.1 46.7 129 4810 0.35 99.0 0.54 
MMP c 7.1 ± 44.1 -2.8 1.1 2.20 4.70 772 0.10 86.2 0.50 
∑DEHP d 96.1 ± 249 8.7 36.3 54.5 92.8 4530 - - - 
∑DBP  e 206 ± 478 12.7 78.9 126 215 8830 - - - 







Table 3.5. Pearson correlation coefficients among maternal urinary phthalates (n = 380). a Specific gravity-corrected, natural 
log-transformed values, b n = 1 missing value, c sum of DEHP metabolites (MEHP, MEOHP, MEHHP) in nmol/L, d sum of 




Phthalates a MBP MiBP MBzP MEHP MEOHP MEHHP MEP b MMP b ∑DEHP c ∑DBP d ∑BzBP e 
MBP - 0.69 0.69 0.31 0.43 0.38 0.41 0.47 0.41 0.93 0.93 
MiBP <.0001 - 0.53 0.21 0.33 0.31 0.39 0.42 0.32 0.90 0.67 
MBzP  <.0001 <.0001 - 0.28 0.35 0.31 0.34 0.40 0.33 0.65 0.90 
MEHP <.0001 <.0001 <.0001 - 0.80 0.81 0.15 0.23 0.87 0.27 0.31 
MEHHP  <.0001 <.0001 <.0001 <.0001 - 0.98 0.19 0.33 0.97 0.40 0.42 
MEOHP <.0001 <.0001 <.0001 <.0001 <.0001 - 0.17 0.32 0.98 0.37 0.38 
MEP b <.0001 <.0001 <.0001 0.004 0.0003 0.001 - 0.26 0.18 0.42 0.41 
MMP b <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 - 0.31 0.47 0.47 
∑DEHP c <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 0.001 <.0001 - 0.39 0.41 
∑DBP d <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 - 0.87 




Table 3.6. Linear regression of anogenital distance measures at birth in boys regressed on maternal urinary phthalates, in 
ng/mL (n = 171). Bold typeface indicates p < 0.05; multiple imputation used to generate estimates for observations with 
missing values. a Specific gravity-corrected, natural log-transformed values in ng/mL, b corrected for birth weight percentile (Z-
score), c adjusted for maternal age, race, education, cigarette smoking, and corrected for birth weight percentile (Z-score), d 
excluding n = 1 influential observation, e sum of DEHP metabolites (MEHP, MEOHP, MEHHP) in nmol/L, f sum of DBP 
metabolites (MiBP, MBP) in nmol/L, g sum of BzBP metabolites (MBzP, MBP) in nmol/L.   
Phthalates a Anopenile Distance Anoscrotal Distance β b (95% CI) P-value βadj c (95% CI) P-value β b (95% CI) P-value βadj c (95% CI) P-value 
MBP -0.84  (-1.88, 0.19) 0.11 
-1.01  
(-2.13, 0.11) 0.08 
1.22  
(0.31, 2.12) 0.01 
0.99  
(0.01, 1.96) 0.05 
MiBP -0.52  (-1.76, 0.72) 0.41 
-0.68  
(-2.00, 0.64) 0.31 
1.46  
(0.39, 2.54) 0.01 
1.14  
(-0.004, 2.27) 0.05 
MBzP -0.11  (-0.91, 0.69) 0.79 
-0.25  
(-1.11, 0.62) 0.57 
0.95  
(0.25, 1.65) 0.01 
0.75  
(0.001, 1.49) 0.05 
MEHP -1.53  (-2.88, -0.17) 0.03 
-1.57  
(-2.94, -0.20) 0.02 
0.09  
(-1.13, 1.32) 0.88 
-0.10  
(-1.31, 1.11) 0.87 
MEOHP -1.04  (-2.32, 0.25) 0.11 
-1.00  
(-2.29, 0.30) 0.13 
-0.05  
(-1.20, 1.10) 0.93 
-0.47 d  
(-1.77, 0.83) 0.48 
MEHHP -0.85  (-2.04, 0.33) 0.16 
-0.84  
(-2.04, 0.35) 0.17 
0.05  
(-1.01, 1.11) 0.93 
0.05  
(-0.99, 1.10) 0.92 
MEP -0.43  (-1.02, 0.15) 0.15 
-0.47 
 (-1.08, 0.15) 0.13 
0.38  
(-0.14, 0.90) 0.16 
0.21  
(-0.33, 0.74) 0.46 
MMP -0.40  (-1.56, 0.76) 0.50 
-0.44  
(-1.61, 0.73) 0.46 
0.49  
(-0.53, 1.52) 0.35 
0.36  
(-0.66, 1.38) 0.49 
∑DEHP e -0.94  (-1.95, 0.08) 0.07 
-0.93  
(-1.96, 0.09) 0.07 
0.03  
(-0.88, 0.94) 0.94 
0.02 
(-0.89, 0.92) 0.97 
∑DBP f -0.62  (-1.60, 0.36) 0.21 
-0.79  
(-1.86, 0.28) 0.15 
1.24  
(0.39, 2.08) 0.004 
1.01  
(0.08, 1.93) 0.03 
∑BzBP g -0.45  (-1.27, 0.38) 0.29 -0.62 (-1.52, 0.28) 0.18 
1.08  
(0.36, 1.80) 0.003 
0.89  





Table 3.7. Linear regression of anogenital distance measures at birth in boys on tertiles of maternal urinary phthalates (ng/mL) 
(n = 171). Bold typeface indicates p < 0.05; we used multiple imputation to generate estimates for observations with missing 
values. a Specific gravity-corrected, natural log-transformed values, b 1st tertile is the reference category; p-value from linear 
models using continuous exposures, c adjusted for age, race, education, cigarette smoking, and corrected for birthweight 
percentile (Z-score), d excluding n=1 influential observation, e molar sum of DEHP metabolites (MEHP, MEOHP, MEHHP) in 
nmol/L, f molar sum of DBP metabolites (MiBP, MBP) in nmol/L, g molar sum of BzBP metabolites (MBzP, MBP) in nmol/L.   
Phthalates a Tertiles b Anopenile distance Anoscrotal distance β c 95% CI p β c 95% CI P 
MBP 2nd  -2.31 -4.30, -0.31 0.02 0.26 -1.51, 2.03 0.77 
 3rd -2.61 -4.77, -0.45 0.02 1.03 -0.88, 2.94 0.29 
MiBP 2nd  -0.60 -2.62, 1.41 0.56 0.94 -0.82, 2.69 0.29 
 3rd -1.23 -3.47, 1.01 0.28 1.26 -0.68, 3.20 0.21 
MBzP  2nd  -1.26 -3.38, 0.86 0.24 2.14 0.35, 3.93 0.02 
 3rd -1.29 -3.47, 0.89 0.25 2.12 0.30, 3.95 0.02 
MEHP 2nd  1.30 -1.14, 3.74 0.30 1.71 -0.47, 3.88 0.12 
 3rd -1.60 -3.97, 0.76 0.19 0.30 -1.81, 2.41 0.78 
MEOHP  2nd  -2.54 -4.62, -0.47 0.02 -0.01 -1.87, 1.84 0.99 
 3rd -2.82 -4.82, -0.82 0.01 -0.36 d -2.14, 1.42 0.69 
MEHHP 2nd  -2.31 -4.37, -0.25 0.02 1.08 -0.74, 2.91 0.24 
 3rd -2.70 -4.76, -0.63 0.01 0.36 -1.46, 2.19 0.69 
MEP 2nd  -0.48 -2.58, 1.61 0.65 -0.96 -2.79, 0.87 0.30 
 3rd -1.37 -3.43, 0.70 0.20 0.12 -1.69, 1.93 0.90 
MMP 2nd  -0.64 -2.68, 1.41 0.54 0.21 -1.58, 2.01 0.82 
 3rd -1.35 -3.47, 0.77 0.21 -0.04 -1.91, 1.82 0.96 
∑DEHP e 2nd  -1.71 -3.85, 0.42 0.11 1.03 -0.86, 2.92 0.29 
 3rd -2.65 -4.74, -0.57 0.01 0.51 -1.33, 2.35 0.59 
∑DBP f 2nd  -0.93 -2.93, 1.07 0.36 0.83 -0.90, 2.55 0.35 
 3rd -1.35 -3.59, 0.89 0.24 2.01 0.08, 3.94 0.04 
∑BzBP g 2nd  0.16 -1.94, 2.26 0.88 1.25 -0.57, 3.08 0.18 





Table 3.8. Linear regression of anogenital distance measures at birth in boys regressed on phthalates (ng/mL), by race. Bold 
indicates p < 0.05; multiple imputation generated estimates for missing values. a SG-corrected, log-transformed values, b 
Corrected for birth weight, c adjusted for age, education, smoking, and birth weight, d  P-value for cross-product term race x 
phthalates in non-stratified multivariable regression, e sum of DEHP (MEHP, MEHHP, MEOHP) in nmol/L, f  sum of DBP 
(MiBP, MBP) in nmol/L, g sum of BzBP (MBzP, MBP) in nmol/L, h excluding n = 1 influential observation.  
Phthalates a 
Caucasian (n = 92) African American (n = 79) 
P-value d β b (95% CI) βadj c (95% CI) β b (95% CI) βadj  c (95% CI) 
Anopenile distance:     
  MBP -1.20 (-2.76, 0.37) -1.47 (-3.12, 0.19) -0.76 (-2.29, 0.77) -0.61 (-2.18, 0.96) 0.61 
  MiBP -0.59 (-2.55, 1.38) -0.68 (-2.67, 1.30) -0.75 (-2.47, 0.97) -0.71 (-2.48, 1.06) 0.93 
  MBzP  -0.14 (-1.28, 0.99) -0.28 (-1.45, 0.89) -0.25 (-1.54, 1.04) -0.18 (-1.52, 1.16) 0.98 
  MEHP -1.29 (-3.23, 0.66) -1.23 (-3.18, 0.72) -2.03 (-3.97, -0.09) -2.08 (-4.06, -0.09) 0.56 
  MEOHP  -0.82 (-2.61, 0.97) -0.80 (-2.60, 1.00) -1.36 (-3.27, 0.55) -1.45 (-3.41, 0.51) 0.60 
  MEHHP -0.88 (-2.60, 0.84) -0.85 (-2.57, 0.88) -0.82 (-2.49, 0.85) -0.95 (-2.66, 0.75) 0.90 
  MEP  -0.62 (1.54, 0.30) -0.67 (-1.60, 0.36) -0.39 (-1.20, 0.42) -0.26 (-1.09, 0.56) 0.58 
  MMP  -0.51 (-1.98, 0.95) -0.56 (-2.07, 0.94) -0.27 (-2.46, 1.92) -0.38 (-2.57, 1.81) 0.94 
  ∑DEHP e -0.87 (-2.36, 0.63) -0.85 (-2.35, 0.65) -1.04 (-2.44, 0.37) -1.12 (-2.55, 0.31) 0.77 
  ∑DBP f -0.88 (-2.38, 0.61) -1.09 (-2.66, 0.47) -0.64 (-2.09, 0.82) -0.51 (-2.01, 0.98) 0.73 
  ∑BzBP g -0.61 (-1.81, 0.58) -0.82 (-2.07, 0.44) -0.48 (-1.80, 0.83) -0.37 (-1.73, 0.99) 0.76 
Anoscrotal distance:     
  MBP 1.18 (-0.11, 2.46) 1.28 (-0.08, 2.63) 0.38 (-1.03, 1.79) 0.39 (-1.08, 1.86) 0.41 
  MiBP 1.69 (0.11, 3.28) 1.69 (0.09, 3.28) 0.28 (-1.30, 1.87) 0.39 (-1.27, 2.05) 0.25 
  MBzP  0.95 (0.04, 1.87) 0.89 (-0.05, 1.83) 0.26 (-0.92, 1.45) 0.36 (-0.89, 1.61) 0.39 
  MEHP -0.93 h (-2.89, 1.03) -0.92 h (-2.86, 1.03) -0.19 (-2.02, 1.64) -0.03 (-1.93, 1.88) 0.61 
  MEOHP  -1.02 h (-2.89, 0.84) -1.04 h (-2.91, 0.83) -0.07 (-1.84, 1.71) 0.11 (-1.74, 1.97) 0.56 
  MEHHP -1.06 h (-2.81, 0.68) -1.05 h (-2.79, 0.69) 0.20 (-1.33, 1.74) 0.34 (-1.26, 1.94) 0.39 
  MEP  0.12 (-0.65, 0.89) 0.08 (-0.68, 0.85) 0.18 (-0.57, 0.93) 0.21 (-0.56, 0.98) 0.76 
  MMP  0.65 (-0.55, 1.86) 0.69 (-0.54, 1.91) -0.24 (-2.25, 1.77) -0.25 (-2.30, 1.79) 0.48 
  ∑DEHP e -0.75 h (-2.22, 0.72) -0.75 h (-2.20, 0.71) 0.06 (-1.24, 1.36) 0.18 (-1.18, 1.54) 0.52 
  ∑DBP f 1.25 (0.04, 2.46) 1.31 (0.05, 2.58) 0.35 (-0.99, 1.69) 0.40 (-1.00, 1.79) 0.35 




Table 3.9. Linear regression of anogenital distance measures at birth in boys on tertiles of maternal urinary phthalates (ng/mL), 
by race. Bold typeface indicates p < 0.05; we used multiple imputation to generate estimates for observations with missing 
values, including education (n = 5) among Caucasians, and education (n = 10) and birth weight percentile Z-score (n = 2) 
among African Americans a Specific gravity-corrected, natural log-transformed values; b 1st tertile (not shown) is the reference 
category; c adjusted for maternal age, education, cigarette smoking, and corrected for birthweight percentile (Z-score); d 
excluding n = 1 influential observation; e sum of DEHP metabolites (MEHP, MEOHP, MEHHP) in nmol/L; f sum of DBP 






Anopenile distance Anoscrotal distance 
Caucasian (n = 92) African American (n = 79) Caucasian (n = 92) African American  (n = 79) 
β c (95% CI) P-value β 
c (95% CI) P-value β c (95% CI) P-value β 
c (95% CI) P-value 
MBP 2nd -2.77  (-5.45, -0.10) 0.04 
-1.85  
(-5.31, 1.60) 0.29 
0.74  
(-1.51, 2.99) 0.52 
-2.08  
(-5.31, 1.15) 0.21 
 3rd -3.64  (-7.16, -0.12) 0.04 
-2.04  
(-5.12, 1.03) 0.19 
1.29  





MiBP 2nd -0.55  (-3.36, 2.26) 0.70 
-0.66  
(-3.87, 2.55) 0.69 
1.45  
(-0.83, 3.73) 0.21 
-0.79  
(-3.78, 2.21) 0.61 
 3rd -2.02  (-5.46, 1.43) 0.25 
-0.64  
(-3.74, 2.47) 0.69 
1.97  
(-0.83, 4.78) 0.16 
-0.14  
(-3.03, 2.76) 0.93 
MBzP  2nd -1.80  (-4.76, 1.17) 0.24 
-0.74  
(-4.20, 2.72) 0.67 
1.74  
(-0.68, 4.16) 0.16 
0.76  
(-2.48, 3.99) 0.65 
 3rd -1.34  (-4.52, 1.84) 0.41 
-1.14  
(-4.49, 2.21) 0.50 
1.36 
 (-1.24, 3.96) 0.31 
0.70  
(-2.43, 3.83) 0.66 
MEHP 2nd 0.55  (-3.02, 4.12) 0.76 
2.94  
(-0.50, 6.38) 0.09 
0.57  
(-2.38, 3.52) 0.71 
3.00  
-0.35, 6.35) 0.08 
 3rd -1.53  (-5.09, 2.04) 0.40 
-1.23  
(-4.40, 1.95) 0.45 
0.21  
(-2.75, 3.16) d 0.89 
0.29  
(-2.80, 3.39) 0.85 




(-6.40, 0.16) (-4.87, 0.55) (-1.94, 3.52) (-3.84, 1.37) 
 3rd -3.38  (-6.54, -0.22) 0.04 
-2.71  
(-5.34, -0.07) 0.04 
-0.55  
(-3.19, 2.09) d 0.68 
-0.19  
(-2.70, 2.33) 0.88 
MEHHP 2nd -2.73  (-6.01, 0.56) 0.10 
-2.20  
(-4.92, 0.53) 0.11 
1.85  
(-0.85, 4.55) 0.18 
-0.22  
(-2.82, 2.38) 0.87 
 3rd -3.46  (-6.77, -0.15) 0.04 
-2.26  
(-4.94, 0.42) 0.09 
0.26  
(-2.48, 3.00) d 0.85 
0.33  
(-2.23, 2.88) 0.80 
MEP 2nd 0.15  (-2.70, 2.99) 0.92 
-1.10  
(-4.48, 2.29) 0.52 
-0.90  
(-3.26, 1.45) 0.45 
-0.96  
(-4.11, 2.19) 0.55 
 3rd -2.05  (-4.94, 0.85) 0.17 
-1.00  
(-4.24, 2.25) 0.55 
-0.32  
(-2.72, 2.07) 0.79 
0.43  
(-2.59, 3.44) 0.78 
MMP 2nd -1.84  (-4.67, 0.99) 0.20 
1.06  
(-2.08, 4.20) 0.51 
0.78 





 3rd -1.60  (-4.71, 1.52) 0.32 
-0.52  
(-3.58, 2.54) 0.74 
0.09  
(-2.49, 2.66) 0.95 
-0.45  
(-3.34, 2.44) 0.76 
∑DEHP e 2nd -1.83  (-5.20, 1.54) 0.29 
-2.11  
(-5.05, 0.83) 0.16 
2.00  
(-0.76, 4.76) 0.16 
-0.71  
(-3.54, 2.11) 0.62 
 3rd -3.13  (-6.49, 0.24) 0.21 
-2.51  
(-5.20, 0.17) 0.07 
0.59  
(-2.17, 3.36) d 0.67 
0.25  
(-2.30, 2.80) 0.85 
∑DBP f 2nd -1.91  (-4.63, 0.82) 0.17 
0.80  
(-2.62, 4.21) 0.65 
1.24  
(-0.97, 3.45) 0.27 
-0.81  
(-3.99, 2.37) 0.62 
 3rd -2.53  (-6.18, 1.12) 0.17 
0.08  
(-3.02, 3.18) 0.96 
2.92  
(-0.05, 5.89) 0.05 
0.38  
(-2.50, 3.26) 0.80 
∑BzBP g 2nd -0.22  (-3.05, 2.61) 0.88 
0.75  
(-2.85, 4.35) 0.68 
1.76  
(-0.54, 4.07) 0.13 
-0.40  
(-3.78, 2.97) 0.82 
 3rd -2.00  (-5.39, 1.38) 0.25 
-0.49  










Table 3.10. Linear regression of anogenital distance measures at birth in girls on urinary phthalates (n = 128). Bold indicates p 
< 0.05; we used multiple imputation to generate estimates for missing values. a SG-corrected, natural log-transformed values in 
ng/mL, b corrected for birth weight percentile (Z-score), c adjusted for maternal age, race, education, cigarette smoking, and 
corrected for birth weight percentile (Z-score), d n=1 missing observation, e sum of DEHP metabolites (MEHP, MEHHP, 
MEOHP) in nmol/L, f sum of DBP metabolites (MiBP, MBP) in nmol/L, g sum of BzBP metabolites (MBzP, MBP) in nmol/L. 
Phthalatea 
Anoclitoral Distance Anofourchette Distance 
β b (95% CI) P-value βadj 
c (95% CI) P-value β b (95% CI) P-value βadj c (95% CI) P-value 
MBP 0.15  (-0.86, 1.17) 0.77 
-0.15  
(-1.33, 1.02) 0.80 
-0.01  
(-0.65, 0.64) 0.98 
-0.32  
(-1.04, 0.41) 0.40 
MiBP 0.10  ( -0.91, 1.10) 0.85 
-0.19  
(-1.39, 1.00) 0.75 
0.72 d  
(0.09, 1.35) 0.03 
0.62 d  
(-0.12, 1.35) 0.10 
MBzP 0.56  (-0.20, 1.32) 0.15 
0.48  
(-0.38, 1.34) 0.28 
0.34  
(-0.14, 0.82) 0.17 
0.23  
(-0.31, 0.76) 0.41 
MEHP -0.98  (-2.38, 0.42) 0.17 
-1.17  
(-2.60, 0.26) 0.11 
-0.53  
(1.42, 0.37) 0.25 
-0.69  
(-1.58, 0.20) 0.13 
MEOHP -0.70  (-2.12, 0.71) 0.33 
-0.86  
(-2.30, 0.58) 0.24 
-0.42  
(-1.32, 0.49) 0.36 
-0.49  
(-1.39, 0.40) 0.28 
MEHHP -0.83 (-2.05, 0.39) 0.18 
-0.95  
(-2.18, 0.28) 0.13 
-0.38  
(-1.16, 0.40) 0.33 
-0.48  
(-1.24, 0.29) 0.22 
MEP -0.29 
d  
(-0.86, 0.28) 0.32 
-0.42 d  
(-1.02, 0.18) 0.17 
0.10 d  
(-0.26, 0.47) 0.58 
0.01 d  
(-0.37, 0.38) 0.98 
MMP -0.25 
d  
(-1.41, 0.92) 0.68 
-0.32 d  
(-1.60, 0.96) 0.62 
0.18  
(-0.56, 0.91) 0.64 
-0.09  
(-0.88, 0.70) 0.83 
∑DEHP e -0.60  (-1.56, 0.36) 0.22 
-0.71  
(-1.69, 0.26) 0.15 
-0.31  
(0.93, 0.30) 0.31 
-0.38  
(-0.99, 0.23) 0.22 
∑DBP f 0.23  (-0.66, 1.12) 0.61 
-0.01  
(-1.08, 1.06) 0.99 
0.41  
(-0.15, 0.97) 0.15 
0.23  
(-0.43, 0.90) 0.50 
∑BzBP g 0.40  (-0.37, 1.18) 0.31 
0.26  
(-0.65, 1.18) 0.57 
0.18  
(-0.32, 0.68) 0.56 
-0.01  





Table 3.11. Linear regression of anogenital distance measures at birth in girls on urinary phthalates (ng/mL), stratified by race. 
Bold typeface p < 0.10 for cross-product term race x phthalates; multiple imputation used to generate estimates for missing 
values. a SG-corrected, log-transformed values, b corrected for birth weight percentile, c adjusted for age, education, cigarette 
smoking, and corrected for birth weight percentile, d  p-value for cross-product term race x phthalates, e excluding n = 1 
observation, f sum of MEHP, MEOHP, MEHHP in nmol/L, h sum of MiBP, MBP in nmol/L, i sum of MBzP, MBP in nmol/L. 
Phthalates a Caucasian (n = 61) African American (n = 67) P-value d β b (95% CI) βadj c (95% CI) β b (95% CI) βadj c (95% CI) 
Anoclitoral distance:         
  MBP 1.54 (-0.68, 3.76) 1.24 (-1.07, 3.54) -0.74 (-2.01, 0.52) -0.79 (-2.10, 0.52) 0.06 
  MiBP 1.25 (-0.98, 3.49) 1.05 (-1.23, 3.33) -0.85 (-2.15, 0.46) 0.01 e (-1.39, 1.41) 0.21 
  MBzP  0.67 (-0.65, 1.98) 0.55 (-0.83, 1.92) 0.38 (-0.72, 1.48) 0.45 (-0.68, 1.59) 0.64 
  MEHP -1.89 (-5.44, 1.67) -2.45 (-6.13, 1.23) -0.95 (-2.45, 0.55) -0.69 (-2.16, 0.79) 0.43 
  MEOHP  0.03 (-2.77, 2.82) -0.28 (-3.13, 2.57) -1.20 (-2.81, 0.42) -1.04  (-2.61, 0.53) 0.49 
  MEHHP -0.75 (-3.20, 1.70) -0.96 (-3.44, 1.51) -1.00 (-2.38, 0.39) -0.85 (-2.19, 0.50) 0.94 
  MEP  0.71 e (-0.33, 1.75) 0.63 e (-0.42, 1.67) -1.05 (-1.82, -0.27) -1.12 (-1.89, -0.35) 0.01 
  MMP  -0.48 (-2.32, 1.37) -0.72 (-2.67, 1.24) -0.47 (-2.20, 1.27) -1.18 e (-3.10, 0.73) 0.64 
  ∑DEHP f -0.36 (-2.27, 1.55) -0.58 (-2.53, 1.36) -0.82 (-1.92, 0.27) -0.69 (-1.75, 0.37) 0.76 
  ∑DBP g 1.41 (-0.40, 3.23) 1.22 (-0.65, 3.08) -0.80 (-2.03, 0.43) -0.77 (-2.05, 0.52) 0.04 
  ∑BzBP h 1.07 (-0.34, 2.47) 0.92 (-0.55, 2.38) -0.34 (-1.48, 0.80) -0.36 (-1.56, 0.84) 0.09 
Anofourchette distance:        
  MBP 0.12 (-1.15, 1.39) 0.35 (-0.97, 1.66) -0.66 (-1.54, 0.21) -0.62 (-1.56, 0.32) 0.26 
  MiBP 0.64 (-0.62, 1.90) 0.82 (-0.46, 2.10) 0.37 (-0.55, 1.28) 0.59 (-0.37, 1.55) 0.74 
  MBzP  0.21 (-0.53, 0.96) 0.33 (-0.45, 1.11) 0.03 (-0.73, 0.80) 0.17 (-0.64, 0.99) 0.77 
  MEHP -0.48 (-2.50, 1.53) -0.35 (-2.46, 1.77) -0.84 (-1.88, 0.20) -0.76 (-1.81, 0.29) 0.74 
  MEOHP  0.01 (-1.57, 1.58) 0.17 (-1.44, 1.78) -0.87 (-1.99, 0.26) -0.77 (-1.90, 0.36) 0.34 
  MEHHP -0.02 (-1.41, 1.36) 0.07 (-1.34, 1.48) -0.77 (-1.73, 0.19) -0.70 (-1.66, 0.26) 0.37 
  MEP  0.04 (-0.48, 0.56) 0.07 (-0.45, 0.60) -0.08 (-0.64, 0.48) -0.05 (-0.63, 0.53) 0.71 
  MMP  -0.39 (-1.43, 0.65) -0.37 (-1.42, 0.74) 0.17 (-1.02, 1.37) 0.23 (-1.00, 1.47) 0.50 
  ∑DEHP f -0.10 (-1.18, 0.98) -0.001 (-1.10, 1.10) -0.60 (-1.36, 0.16) -0.53 (-1.29, 0.23) 0.43 
  ∑DBP g 0.36 (-0.68, 1.40) 0.52 (-0.54, 1.60) -0.07 (-0.93, 0.80) 0.09 (-0.84, 1.03) 0.50 




Table 3.12. Linear regression of anogenital distance measures at birth in girls on tertiles of maternal urinary phthalates 
(ng/mL), by race. Bold indicates p < 0.05; we used multiple imputation to generate estimates for observations with missing 
values, including education (n = 1) and cigarette smoking (n = 2) among Caucasians, and education (n = 1) and cigarette 
smoking (n = 1) among African Americans. a Specific gravity-corrected, natural log-transformed values, b 1st tertile (not 
shown) is the reference category, c adjusted for maternal age, education, cigarette smoking, and corrected for birthweight 
percentile (Z-score), d excluding n=1 influential observation, e  excluding n=1 missing observation, f sum of DEHP metabolites 
(MEHP, MEOHP, MEHHP) in nmol/L, g sum of DBP metabolites (MiBP, MBP) in nmol/L, h sum of BzBP metabolites 
(MBzP, MBP) in nmol/L. 
Phthalatea Tertileb 
Anoclitoral distance Anofourchette distance 
Caucasian (n = 61) African American   (n =67) Caucasian (n = 61) 
African American  
(n = 67) 




β c (95% CI) P-value β 
c (95% CI) P-value β 
c (95% CI) P-value 
MBP 2nd 1.09  (-1.31, 3.49) 0.37 
-0.75  
(-3.08, 1.58) 0.53 
0.72  
(-0.63, 2.08) 0.29 
-0.80  
(-2.51, 0.90) 0.36 
 3rd 0.60  (-3.12, 4.32) 0.75 
-2.54  
(-4.80, -0.29) 0.02 
0.11  
(-1.99, 2.20) 0.92 
-1.35  
(-3.01, 0.30) 0.11 
MiBP 2nd 2.31  (-0.09, 4.72) 0.06 
-1.21  
(-3.67, 1.24) 0.33 
0.06  
(-1.34, 1.46) 0.93 
-0.16  
(-1.99, 1.67) 0.86 
 3rd -0.47  (-4.14, 3.20) 0.80 
-1.10  
(-3.36, 1.15) d 0.34 
1.00  
(-1.14, 3.13) 0.36 
0.88 
 (-0.79, 2.56) 0.30 
MBzP  2nd 2.43  (-0.25, 5.12) 0.08 
-0.01  
(-2.53, 2.51) 0.99 
0.80  
(-0.75, 2.34) 0.31 
0.75  
(-1.05, 2.55) 0.41 
 3rd 0.01  (-3.15, 3.17) 0.99 
0.31  
(-2.22, 2.83) 0.81 
0.46  
(-1.36, 2.29) 0.62 
0.59  
(-1.21, 2.40) 0.52 
MEHP 2nd 1.04  (-2.13, 4.21) 0.52 
-0.43  
(-2.59, 1.73) 0.70 
-1.33  
(-3.15, 0.50) 0.16 
-1.03  
(-2.59, 0.52) 0.19 
 3rd -4.03  (-8.29, 0.22) 0.06 
-1.81  
(-3.97, 0.36) 0.10 
-0.40  
(2.85, 2.06) 0.75 
-0.84  





MEOHP  2nd 0.06  (-2.54, 2.65) 0.96 
-0.80  
(-3.00, 1.39) 0.47 
0.18  
(-1.29, 1.64) 0.81 
-0.70  
(-2.28, 0.88) 0.39 
 3rd -0.12  (-3.19, 2.94) 0.94 
-1.55  
(-3.62, 0.51) 0.14 
-0.17 
(-1.90, 1.56) 0.85 
-0.78  
(-2.28, 0.71) 0.30 
MEHHP 2nd -0.84  (-3.44, 1.77) 0.53 
-0.01  
(-2.22, 2.21) 0.99 
-0.53  
(-2.02, 0.95) 0.48 
-0.70  
(-2.29, 0.90) 0.39 
 3rd -1.66  (-4.59, 1.26) 0.27 
-1.22  
(-3.28, 0.84) 0.25 
-0.03  
(-1.70, 1.64) 0.97 
-0.52  
(-2.00, 0.97) 0.50 
MEP e 2nd 0.87  (-1.72, 3.46) 0.51 
-1.08  
(-3.26, 1.10) 0.31 
-0.30  
(-1.79, 1.19) 0.69 
-0.62  
(-2.24, 1.00) 0.46 
 3rd 1.52  (-1.75, 4.78)d 0.36 
-3.01  
(-5.36, -0.65) d 0.01 
-0.21  
(-2.02, 1.60) 0.82 
-0.56  
(-2.30, 1.19) 0.53 
MMP e 2nd 0.05  (-2.65, 2.74) 0.97 
-1.28 
(-3.64, 1.08) 0.30 
1.84  
(0.42, 3.25) 0.01 
-0.32  
(-2.00, 1.37) 0.71 
 3rd -0.70  (-3.72, 2.32) 0.65 
-1.66  
(-4.00, 0.70) 0.23 
-0.66  
(-2.24, 0.93) 0.42 
1.08  
(-0.57, 2.75) 0.20 
∑DEHP f 2nd -0.56  (-3.27, 2.16) 0.69 
-1.04  
(-3.17, 1.09) 0.34 
-0.32 
(-1.86, 1.22) 0.68 
-0.91  
(-2.44, 0.63) 0.25 
 3rd -0.96  (-3.94, 2.03) 0.53 
-1.25  
(-3.39, 0.89) 0.25 
0.08  
(-1.61, 1.78) 0.92 
-0.64  
(-2.17, 0.90) 0.42 
∑DBP g 2nd 1.46  (-1.12, 4.04) 0.27 
-1.63  
(-4.32, 1.06) 0.23 
0.15  
(-1.32, 1.63) 0.84 
-0.42  
(-2.37, 1.53) 0.67 
 3rd 0.63  (-2.91, 4.17) 0.73 
-1.92  
(-4.51, 0.67) 0.15 
0.20  
(-1.82, 2.23) 0.84 
0.23  
(-1.65, 2.11) 0.81 
∑BzBP h 2nd 2.30  (-0.10, 5.00) 0.09 
-1.01  
(-3.42, 1.41) 0.41 
0.02  
(-1.56, 1.59) 0.98 
-1.09  
(-2.81, 0.64) 0.22 
 3rd -0.21  (-3.44, 3.00) 0.89 
-1.48  
(-3.89, 0.93) 0.23 
0.10  
(-1.77, 1.97) 0.92 
-1.24  





Figure 3.1. Landmarks for measurement of anogenital distances. In males (A), APD was 
measured from the anterior margin of the anus to the anterior base of the penis and ASD 
was measured from the anterior margin of the anus to the base of the scrotum. In females 
(B), measurements were made from the anterior margin of the anus to the base of the 





Figure 3.2. Linear regression of anoclitoral distance measured at birth (mm) on maternal 
urinary phthalates (ng/mL), stratified by race (n = 128). Phthalate concentrations are 
specific gravity-corrected and natural log-transformed, and have been adjusted for 
maternal age, education, cigarette smoking, and corrected for birthweight percentile (Z-




Chapter 4. Assessing the prevalence and endocrine disrupting potential of DINCH, 
a novel phthalate replacement chemical 
4.1 Introduction 
With increasing evidence of phthalate-associated endocrine disruption over past 
decades comes growing awareness of these compounds from both the general public and 
governmental regulatory bodies. As a result, some companies are seeking phthalate 
alternatives for use in products in order to satisfy consumers and comply with stricter 
governmental regulations (CPSC 2014). One of the most common phthalate replacements 
is di(isononyl) cyclohexane-1,2-dicarboxylate (DINCH; Figure 4.1).  
DINCH is manufactured by catalytic hydrogenation of the aromatic ring of 
diisononyl phthalate (DINP) and has been commercialized as Hexamoll® DINCH® 
(BASF, Ludwigshafen, Germany) since 2002 (Figure 4.1). DINCH was introduced to 
replace high molecular weight phthalates, specifically diethylhexyl phthalate (DEHP) and 
DINP, in sensitive application areas such as toys, medical devices, and food packaging 
(Schütze et al. 2012). DINCH leaches from polyvinyl chloride (PVC) at a slower rate 
than DEHP (Kastner et al. 2012) (although Bernard and colleagues (2015) found the 
difference to be smaller when PVC was placed in a mixture of water and ethanol), but 
resulting products are similar in flexibility and viscosity (Crespo et al. 2007). It is likely 
that DINCH has the same routes of exposure to humans as phthalates, which include 
ingestion, inhalation, and dermal absorption (Giovanoulis et al. 2016). According to the 
manufacturer, 200,000 tons of DINCH were produced in 2014. 
Due to DINCH’s non-aromatic structure, it is considered to be less toxic to 
fertility and reproductive development than DEHP. In vivo toxicological studies have 
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reported that DINCH exposure can exert negative effects on thyroid, liver, and kidney 
functions at high concentrations in rats, however these studies have shown no evidence of 
developmental or reproductive toxicity or endocrine disruption due to DINCH (EFSA 
2006). As a result, the European Food and Safety Authority established a tolerable daily 
intake value of 1 mg/kg bw/day for DINCH (EFSA 2006). 
In the human body, the metabolic degradation of DINCH begins with the partial 
cleavage of the diester into the simple hydrolytic monoester cyclohexane-1,2-
dicarboxylic acid mono isononyl ester (MINCH). The alkyl chain of MINCH is then 
oxidized to produce secondary metabolites, which have been successfully used as urinary 
biomarkers of DINCH exposure (Figure 4.2) (Koch et al. 2013, Silva et al. 2013). Of the 
secondary metabolites, cyclohexane-1,2-dicarboxylic acid-mono(hydroxy-isononyl) ester 
(OH-MINCH) is most abundant, followed by cyclohexane-1,2-dicarboxylic acid-
mono(oxo-isononyl) ester (oxo-MINCH), and cyclohexane-1,2-dicarboxylic acid-
monocarboxy isooctyl ester (cx-MINCH). These three metabolites, which we measure in 
this study, are excreted in urine within 24 hours and represent approximately 13% of a 
single oral DINCH dose (Koch et al. 2013). Two additional groups of extensively 
oxidized DINCH metabolites were recently identified; one of them, MCHxCH 
(cyclohexane-1,2-dicarboxylic acid mono carboxyhexyl ester), was determined to be a 
significant DINCH metabolite, second only to OH-MINCH (Schütze et al. 2016). Less 
than 1% of DINCH exposures are excreted as MINCH, thus the primary metabolite is not 
a useful biomarker of DINCH exposure. Additionally, MINCH and the secondary 
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metabolites are broken down into cyclohexane-1,2-dicarboxylic acid (CHDA), which is 
also not a useful biomarker because it is not specific to DINCH exposure. 
Biomonitoring efforts in the U.S. and worldwide have demonstrated that humans 
are exposed to detectable amounts of DINCH, and exposure has been steadily increasing 
since its introduction in 2002. Between 2002 and 2012, the percentage of urine samples 
with detectable concentrations of DINCH metabolites increased from 0% to 21% in the 
U.S. and to 98% in Germany (Silva et al. 2013, Schütze et al. 2014). Despite this 
increase, urinary concentrations of DINCH metabolites remain low relative to phthalates. 
A study conducted in Sweden that measured oxo-MINCH found that urinary 
concentrations increased from 0.2 to 0.7 ng/mL between 2009 and 2014, increasing by 
20% each year (Gyllenhammar et al. 2017). In addition to urine, DINCH metabolites 
have also been detected in fingernails, dust, and infant mattress covers (Nagorka et al. 
2011, Boor et al. 2015, Fromme et al. 2016, Giovanoulis et al. 2016). 
Due to the high exposure potential of a fetus during gestation, pregnant women 
are a vulnerable population for phthalate and DINCH exposures alike. Unlike phthalates, 
however, the endocrine-disrupting potential of DINCH and its metabolites remain largely 
unstudied. The aim of this research was first to determine urinary DINCH metabolite 
concentrations in pregnant women in Charleston, S.C., and second, to assess the potential 
estrogen or progesterone-like activity of DINCH metabolites. The estrogen receptor alpha 
(ESR1) and progesterone receptor beta (PGRB) were selected as potential targets of 
DINCH metabolite activity due to their relevance to fetal development and because the 
activity of these receptors is frequently modified by endocrine disrupting chemicals 
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(Viswanath et al. 2008, Shanle et al. 2011). The progesterone receptor is known as the 
hormone of pregnancy and is involved in preparing the uterus, decreasing maternal 
immune response, dictating the onset of labor, and regulating lactation. Estrogenic 
activities are mediated by ESR1, which is a critical component in the development and 
function of the female reproductive system. Based on the current literature and known 
exposure levels, we hypothesize that urinary DINCH metabolites will be present in our 
population at low concentrations. We also hypothesize that DINCH metabolites will not 
exhibit estrogenic or progesterone-like activity, as they are similar in structure to 
phthalate metabolites which exert antiandrogenic effects.  
 
4.2 Materials and Methods 
Chemicals and Reagents 
OH-MINCH, oxo-MINCH, cx-MINCH, OH-MINCH-d4, and cx-MINCH-d2 
were generous gifts from Dr. Holger Koch (IPA, Bochum, Germany). 4-
methylumbelliferone (4-MeUmb) and its glucuronide were purchased from Sigma 
Aldrich Laboratories, Inc. (St.Louis, MO, USA). Acetonitrile, water (HPLC grade), and 
ethyl acetate were purchased from Honeywell Burdick and Jackson (Morris Plains, NJ, 
USA). Ammonium acetate, acetic acid (98% min.), and monosodium phosphate 
monohydrate anhydrous were purchased from Thermo Fisher Scientific (Waltham, MA, 
USA). Phosphoric acid (85%) and formic acid (98% min.) were purchased from EMD 
Millipore (Billerica, MA, USA). β-glucuronidase (Escherichia coli-K12) was purchased 
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from Roche Biomedical (Mannheim, Germany). All chemicals and reagents were used 
without further purification. 
 
Study Population 
Women from the Charleston area who planned to deliver at the Medical 
University of South Carolina (MUSC) between 2011 and 2014 were recruited to 
participate in a larger study designed to examine the relationship between maternal 
phthalate concentration and prenatal and neonatal genital measurements. All women were 
eligible to participate as long as they were at least 18 years of age, carried a singleton 
fetus, and had pregnancy dating confirmed by a first trimester ultrasound. Women were 
excluded if they were carrying a fetus with genetic anomalies or aneuploidy, using 
progesterone or other steroids, or had pre-gestational diabetes mellitus, hypo- or 
hyperthyroidism, or any other known endocrine disorders.  
Between 18 and 22 weeks of gestation, participants completed a study 
questionnaire, provided a urine specimen, and were evaluated for physical condition and 
relevant pregnancy characteristics. From this overall population (n = 379), urine samples 
from 100 women were selected for measurements of DINCH. Of this subset of 100 
participants, 50 women were African American and 50 were Caucasian. We selected 
women that were representative of high, medium, and low phthalate exposures and 
ensured an even sampling distribution across years 2011 to 2014. Additionally, eight 
urine samples collected at delivery were selected at random for DINCH analysis from 
participants in this subsample. This study and all survey protocols were approved by the 
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institutional review board of MUSC. All participants signed informed consent prior to 
enrollment.  
 
Sample preparation for phthalate metabolite analysis 
Urine was analyzed for a panel of three DINCH metabolites: OH-MINCH, oxo-
MINCH, and cx-MINCH. We did not measure MCHxCH because it had not been 
discovered at the time of this experiment. Urine specimens were collected in sterile glass 
jars at MUSC and transferred to the Hollings Marine Laboratory (Charleston, South 
Carolina) for analysis. After measuring specific gravity at room temperature using a 
handheld refractometer (Atago U.S.A., Inc., Bellevue, WA, USA), the urine was divided 
into 1 mL aliquots and stored under appropriate conditions (-20° C) until analysis.  
Stock solutions of DINCH metabolites, 4-MeUmb, and isotopically-labeled 
metabolites and 4-MeUmb were prepared in acetonitrile (or water for 4-MeUmb 
materials) and stored at 4 °C in Teflon-capped glass bottles. The calibration standards, 
containing native and isotopically-labeled DINCH metabolites and 4-MeUmb, were 
prepared in acetonitrile from stock solutions to create ten unique standard solutions and 
stored at 4 °C in Teflon-capped glass tubes until use. A standard solution of 4-MeUmb 
glucuronide (2 μg/mL) was prepared in water and added to all samples. The 4-
MeUmb/13C4 4-MeUmb peak area ratio was monitored to check the extent of the 
deconjugation reaction with β-glucuronidase. Quality control (QC) materials were 
prepared from a urine pool obtained from multiple anonymous donors.  
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Extraction and analysis methods were based on those previously developed by the 
U.S. Centers for Disease Control and Prevention and the Institute for Prevention and 
Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-
University Bochum (IPA), described elsewhere (Silva et al. 2012, Koch et al. 2013). Pre-
aliquotted urine (1 mL) was thawed, vortex-mixed, and spiked with the internal standard 
(50 μL) containing a mixture of isotopically-labeled analytes, 2 μg/mL 4-MeUmb 
glucuronide solution (25 μL), and 2% β-glucuronidase in ammonium acetate buffer (255 
μL, pH 6.5/1M). The sample was incubated at 37 °C for a minimum of 120 minutes to 
deconjugate the glucuronidated DINCH metabolites. We then added to the sample 40 µL 
acetic acid (98%) to adjust the pH value and 60 μL acetonitrile to stop enzyme activity.  
The urine sample was placed on RapidTrace Station modules (Zymark 
Corporation, Hopkinton, MA, USA) for the automated solid phase extraction procedure. 
The solvent lines were purged with acetonitrile, ethyl acetate, and methanol prior to each 
extraction. Polymeric sorbent-filled cartridges (60 mg, 3 mL; Agilent Bond Elut NEXUS, 
Santa Clara, CA, USA) were conditioned with 1 mL acetonitrile followed by 1 mL pH 2 
phosphate buffer (0.14 M NaH2PO4 in 0.85% [volume fraction] H3PO4) at 1 mL/min. 
Urine samples were loaded onto the cartridge at 1 mL/min. The column was then rinsed 
with 2 mL of 0.1 M formic acid followed by 1 mL of water. Cartridges were dried with 
air for 0.5 minutes. Analytes were eluted with 1 mL acetonitrile followed by 1 mL ethyl 
acetate at 1 mL/min. The eluates were transferred to a TurboVap evaporator (Zymark 
Corporation, Hopkinton, MA, USA) and evaporated to dryness at 55°C under a stream of 
dry nitrogen. The residue was resuspended in 200 μL of Millipore water for analysis. 
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Instrumental analysis of DINCH metabolites 
Samples (5 μL) were injected onto a BetaSil Phenyl column (150 mm x 2.1 mm x 
3.0 μm, Thermo Fisher Scientific) fitted to an Agilent 1200 Series liquid chromatography 
system equipped with a binary pump and autosampler (maintained at 8℃). The solvent 
gradient (flow rate 250 μL/min) started at 25 % of 0.1 % acetic acid in acetonitrile and 
75% of 0.1% acetic acid in water and then increased to 100% of 0.1% acetic acid in 
acetonitrile by 30 minutes before reverting back to primary conditions for 10 minutes 
(Table 4.1). Samples were injected onto an AB Sciex API4000 QTRAP hybrid triple 
quadrupole/linear ion trap mass spectrometer (Framingham, MA, USA) equipped with 
electrospray ionization. The mass spectrometers were tuned and optimized for each 
analyte (Table 4.2, Table 4.3). Two ion transitions were monitored for each analyte in 
multiple reaction monitoring mode (Table 4.3). A representative chromatogram of 
DINCH metabolites is shown in Figure 4.3. The system was controlled by Analyst 
software, version 1.5.2 (AB Sciex, Framingham, MA, USA). 
Standard QC and reagent blank samples were included in each analytical batch 
along with participant samples. Analytes were quantified using calibration curves 
constructed with peak area ratio of each analyte to its isotopically labeled internal 
standard versus standard concentration. Oxo-MINCH was determined semi-quantitatively 
by using the external calibration curve of OH-MINCH and D4-OH-MINCH as the 
internal standard. The limit of detection (LOD) for each metabolite was estimated as the 
mean of the control blanks plus three times the standard deviation of the mean, or the 




Statistical analyses were limited to metabolites with a detection frequency (DF) of 
≥ 50%. Urinary concentrations of OH-MINCH metabolites below the detection limit 
were assigned a value equal to half the detection limit for statistical analysis. 
Concentrations of urinary DINCH metabolites were adjusted for specific gravity (SG) to 
account for urinary dilution, according to the following formula: Pc = P((SGM – 1)/(SG – 
1)), where Pc is the SG-corrected phthalate concentration (ng/mL), P is the observed 
phthalate concentration (ng/mL), SGM is the mean SG for all study samples, and SG is 
the specific gravity of the individual urine sample (Boeniger et al. 1993).  
 All metabolite concentrations failed the Shapiro-Wilk test of normality, therefore 
we utilized nonparametric tests in subsequent analyses. We assessed bivariate 
associations between race, year, sampling time point, and DINCH concentrations by 
Mann-Whitney U test, Kruskal-Wallis test, and Wilcoxon signed-rank test, respectively. 
Correlations between OH-MINCH and values of oxo-MINCH above the LOD (n = 44) 
were determined by Spearman’s rank-order correlation. Statistical analyses were 
performed using IBM SPSS Statistics, version 22 (IBM Corp., Armonk, NY, USA) with 
significance set at α = 0.05. 
 
Transactivation and reporter gene assays 
For human ESR1 and PGRB transactivation assays, HEK293T/17 cells (human 
embryonic kidney; ATCC CRL-11268) were maintained in DMEM (Dulbecco’s 
Modified Eagle Medium, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) 
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containing 10% charcoal/dextran-treated fetal bovine serum (GE Healthcare, Little 
Chalfont, United Kingdom) and Penicillin-Streptomycin (Thermo Fisher Scientific). 
Cells were plated in 96-well dishes at a density of 10,000 cells per well. Twenty-four 
hours after seeding, the cells were transfected with plasmids (0.02 μg/well of ESR1 or 
PGRB in pcDNA3.1, 0.04 μg/well of ERE [estrogen response element] for ERα or 
MMTV [mouse mammary tumor virus promoter] in pGL3 for PGRB), and 0.01 μg/well 
of pRL-tk (reference luciferase) using FuGENE® HD Transfection Reagent according to 
the manufacturer’s protocol (Promega, Madison, WI, USA). 
Twenty-four hours after transfection, cells were dosed with 10-14, 10-13, 10-12, 10-
11, 10-10, 10-9, and 10-8 M E2 for ESR1, 10-12, 10-11, 10-10, 10-9, 10-8, 10-7, and 10-6 M P4 for 
PGRB, or vehicle alone (0.1% dimethyl sulfoxide). MINCH, OH-MINCH, cx-MINCH, 
and oxo-MINCH were tested at 10-9 M, 10-8 M, 10-7 M, 10-6 M, and 10-5 M. Additionally, 
we tested mono-(2-ethylhexyl) phthalate (MEHP) at 10-9 M, 10-8 M, and 10-7 M to 
compare results to a potent phthalate metabolite, as well as 10-7 M of a DINCH 
metabolite mixture (containing MINCH, OH-MINCH, cx-MINCH, and oxo-MINCH) to 
assess for potential mixture effects. A test plate diagram is described in Figure 4.4.  
The cells were lysed after 44 hours of exposure to compounds and the Dual-
Luciferase Reporter Assay System (Promega) and a Microbeta Workstation (Perkin 
Elmer, Walktham, MA, USA) were used to measure firefly and Renilla luminescence 
according to the manufacturers’ recommendations. Each experiment was repeated three 
times with triplicates at each repeat.Human ESR1 and PGRB and reporter constructs 
were kindly provided by Dr. Katsu (Hokkaido University, Japan), and Dr. Gellersen 
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(Endokrinologikum, Hamburg, Germany). All data analyses were performed using 




The LODs for OH-MINCH, oxo-MINCH, and cx-MINCH were 0.04, 0.10, and 
1.0 ng/mL, respectively (Table 4.4). Due in part to the relatively high LOD for cx-
MINCH, we measured detectable concentrations in only one sample. We detected OH-
MINCH in 98% and oxo-MINCH in 44% of the samples (n = 100). As expected, 
detectable levels of OH-MINCH and oxo-MINCH were positively correlated, rs(44) = 
.481, p < 0.01 (Figure 4.5). OH-MINCH, oxo-MINCH, and cx-MINCH were detectable 
in 100%, 50%, and 0% of the delivery urine samples (n = 8), respectively.  
The median (interquartile range) second trimester concentration of OH-MINCH 
was 0.18 (0.21) ng/mL for the overall population, 0.20 (0.24) ng/mL for African 
American women, and 0.12 (0.23) ng/mL for Caucasian women (Table 4.4). After 
adjusting for SG, median (interquartile range) OH-MINCH concentrations were 0.20 
(0.25) ng/mL, 0.23 (0.27) ng/mL, and 0.13 (0.26) ng/mL for the overall population, 
African American women, and Caucasian women, respectively (Table 4.4). The 
maximum SG-adjusted concentration of OH-MINCH was 2.79 ng/mL. A Mann-Whitney 
U test determined that both unadjusted and SG-adjusted OH-MINCH concentrations were 
significantly higher in African American women than in Caucasian women (p = 0.003 for 
unadjusted; p = 0.01 for SG-adjusted; Table 4.4, Figure 4.6). Following the removal of 
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the three extreme outliers (all African Americans), significant differences remained 
between the two groups (p = 0.03 for SG-adjusted concentrations). 
Temporal trends in OH-MINCH exposure 
There were no significant differences in OH-MINCH concentrations between 
years 2011 and 2014 (Table 4.5, Figure 4.7). The median SG-adjusted concentrations 
were 0.23 ng/mL in 2011, 0.22 ng/mL in 2012, 0.20 ng/mL in 2013, and 0.18 ng/mL in 
2014. We also found no significant differences in OH-MINCH concentrations in second 
trimester urine samples (SG-adjusted median: 0.35 ng/mL) compared to paired delivery 
urine samples (SG-adjusted median: 0.13 ng/mL); however, OH-MINCH concentrations 
decreased in seven out of eight paired samples from the 2nd trimester to delivery (Figure 
4.8).  
Transactivation assays 
None of the DINCH metabolites tested demonstrated ESR1 or PGRB 
transactivation activity, even at high concentrations (Figure 4.9, Figure 4.10). Similarly, 
neither MEHP nor the DINCH metabolite mixture elicited estrogenic or progestogenic 
responses. For the first of three experiments, the lowest concentration of MINCH tested 
(10-9 M) exhibited slight PGRB transactivation activity (Figure 4.10), but this was 
determined to be caused by contamination, as the response was not replicated in two 





In this cross-sectional study of 100 pregnant women, we detected at least one 
urinary DINCH metabolite in 98% of the population. Concentrations of DINCH 
metabolites were low; the median concentration of most prevalent metabolite, OH-
MINCH, was 0.18 ng/mL. African American women had higher urinary concentrations 
of OH-MINCH than Caucasian women, and OH-MINCH concentrations were consistent 
between years 2011 and 2014. We found no significant differences in urinary DINCH 
metabolite concentrations between samples collected during the second trimester of 
pregnancy and at delivery. DINCH metabolites did not exhibit estrogenic or 
progestogenic activity when tested on an in vitro transactivation assay.   
We detected OH-MINCH in 98% in samples, and oxo-MINCH and cx-MINCH 
were detected in 44% and 1% of samples, respectively. Our OH-MINCH and oxo-
MINCH DFs are higher, but cx-MINCH DF is lower than previously described for the 
U.S. population in 2012 (DF for OH-MINCH, oxo-MINCH, and cx-MINCH = 19%, 
16%, 21%, respectively) (Silva et al. 2013). The OH-MINCH DF reported here 
resembles DFs from abroad, but our oxo-MINCH and cx-MINCH DFs fall below those 
reported in Germany, Norway, and Sweden. Two studies in Germany reported 98 and 
100% DF for OH-MINCH, 85% and 99% DF for oxo-MINCH, and 88% and 100% DF 
for cx-MINCH in 2011 and 2012 (Schütze et al. 2014, Fromme et al. 2016). The 
Norwegian study reported 85% to 90% DF for OH-MINCH, depending on the time of 
day and 85% DF for cx-MINCH, and the Swedish study reported a DF of 90% for oxo-
MINCH. Taken together, these results suggest DINCH exposure is ubiquitous in our 
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population, and is more prevalent than in the general U.S. population but similar to 
exposures found in European populations. Since the LOD largely determines DFs of low-
concentration compounds, variations in DFs between studies could also be the result of 
discrepancies in measurement sensitivity.  
In addition to being more frequently detected, concentrations of OH-MINCH 
reported here (95th percentile = 0.99 ng/mL) are slightly higher than concentrations 
reported for U.S. females (95th percentile = 0.90 ng/mL) (CDC 2017). Internationally, 
urinary concentrations of OH-MINCH metabolites measured here (median = 0.18 ng/mL) 
are lower than those reported in Portuguese children from 2014 to 2015 (median = 2.14 
ng/mL) (Correia-Sá et al. 2017), German children from 2011 to 2012 (median = 1.7 
ng/mL) (Fromme et al. 2016), Germans in 2012 (geometric mean = 0.4 ng/mL) (Schütze 
et al. 2014), and Australians from 2012 to 2013 (OH-MINCH range = 1.2 to 16.2 ng/mL) 
(Gomez Ramos et al. 2016). Additionally, urinary oxo-MINCH concentrations measured 
here (median = 0.24 ng/mL for values above the LOD) are slightly lower than those 
reported in Swedish first-time mothers from 2009 to 2014 (median = 0.37 ng/mL) 
(Gyllenhammar et al. 2017). The only European study in which DINCH metabolite 
concentrations were similar to concentrations reported here comes from a study of 
Norwegian adults from 2013 to 2014, in which their OH-MINCH creatinine-corrected 
geometric mean and our OH-MINCH SG-adjusted median are both 0.2 ng/mL 
(Giovanoulis et al. 2016). Laws banning the use of certain phthalates are more stringent 
in the European Union, thus we might expect the use of phthalate replacements such as 
DINCH to be more widespread abroad than in the U.S.  
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According to results from NHANES (CDC 2017), OH-MINCH concentrations 
were higher in females compared to males, and the six to 11 year age group had the 
highest concentrations of any age group. They also reported that unadjusted 
concentrations of OH-MINCH were highest in Mexican Americans, followed by non-
Hispanic blacks, then non-Hispanic whites; however, when urine samples were 
creatinine-corrected, non-Hispanic whites had higher OH-MINCH concentrations than 
non-Hispanic blacks. Conversely, we found that both SG-adjusted and unadjusted urinary 
OH-MINCH concentrations were higher in African American women than in Caucasian 
women. Specific information on commercial phthalate replacement use and product 
formulations is not typically disclosed; therefore, we were unsure if DINCH would only 
be used in certain phthalate-free products, or if DINCH implementation would be 
widespread across the consumer market. Because both phthalate and DINCH metabolites 
were found at significantly higher concentrations in African Americans in our population, 
we speculate that DINCH is replacing phthalates in a wide variety of dietary and person 
care products.  
Increasing levels of urinary DINCH metabolites are documented worldwide. In 
addition to the nearly exponential increases in urine sample DFs since 2002 (Silva et al. 
2013, Schütze et al. 2014), researchers are also finding increasing concentrations of 
DINCH in dust samples. In German households, concentrations of DINCH in dust 
climbed from less than 0.3 mg/kg between 2001 and 2006, to 2.2 mg/kg in 2009, to 302 
mg/kg in 2012 (Nagorka et al. 2011, Fromme et al. 2016). We were surprised to find that 
urinary concentrations of DINCH metabolites did not increase from year 2011 to 2014 in 
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our study. In fact, median SG-adjusted OH-MINCH concentrations non-significantly 
decreased each year. These results suggest that while DINCH use may be increasing 
globally, local exposure to DINCH remained consistent from 2011 to 2014. It is possible 
that following an initial replacement of phthalates for DINCH to fulfill governmental 
requirements, little to no further substitution has occurred.  
 To determine if hospitalization was an acute source of DINCH exposure, we 
measured urinary DINCH metabolites in samples collected from eight study participants 
while hospitalized for delivery. Our phthalate metabolite analysis of delivery urine 
samples revealed significant increases in five of the eight metabolites measured (MBP, 
MBzP, MEHP, MEHHP, and MEOHP) relative to samples collected during the second or 
third trimesters, suggesting that medical bags and tubing are acute sources of phthalate 
exposure (Figure 4.11). Conversely, we found no significant differences between urinary 
DINCH metabolite concentrations from the second trimester and at time of delivery in 
eight study participants. Therefore, medical devices used at MUSC from 2011 to 2014 
were not significant sources of DINCH exposure.  
Current U.S. regulations encourage but do not require the replacement of DEHP-
containing PVC materials for medical use. As public awareness of adverse health effects 
associated with DEHP and other phthalates grows, it is likely that hospitals will 
voluntarily replace PVC materials with phthalate-free versions. In fact, Kaiser 
Permanente, the nation’s largest nonprofit health organization, has replaced phthalate-
containing PVC in medical equipment. Anecdotally, intravenous (IV) bags were labeled 
“contains DEHP” at a local (non-MUSC) hospital in the fall of 2015. By June of 2016, at 
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the same hospital, the IV bags had been replaced by ones that were free of DEHP and 
PVC. We hypothesize that as more hospitals replace IV bags and tubing with DEHP-free 
materials, concentrations of urinary DINCH metabolites following hospitalization will 
increase.  
Little is known about the bioactivity of DINCH metabolites in humans. According 
to results from initial rodent-based toxicological testing, high DINCH exposure can cause 
renal toxicity and thyroid hyperplasia, yet it was determined to be neither a reproductive 
toxicant nor an endocrine disruptor (EFSA 2006). Upon testing DINCH metabolites 
individually and in a mixture on a transactivation assay, we found that none of the 
metabolites exhibited estrogenic or progestogenic activity at any doses tested. With the 
exception of the peroxisome proliferator-activated receptor (Lovekamp-Swan et al. 2003, 
Xu et al. 2010), phthalate metabolites do not typically exert their effects by targeting 
hormone receptors; therefore, we were unsure if DINCH metabolites would be bioactive 
at the hormone receptor level or not. Phthalate metabolites reduce the expression of 
enzymes and proteins involved in steroidogenesis, ultimately inhibiting Leydig cell 
production of testosterone (Martinez-Arguelles et al. 2013), so the possibility remains 
that DINCH metabolites may work through alternative steroidogenic pathways. 
Despite our null findings, others have recently discovered potential adverse health 
effects associated with DINCH and its metabolites. In one study, MINCH exerted in vitro 
pro-adipogenic effects on rat primary stromal vascular fraction of adipose tissue, but 
DINCH did not (Campioli et al. 2015). In another in vitro experiment, DINCH exerted a 
biphasic effect on testosterone production in MA-10 and fetal Leydig cells, with high 
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concentrations exerting an inhibitory effect and lower concentrations stimulating 
testosterone production (Boisvert et al. 2016). Additionally, metabolites of DINCH were 
found to be more cytotoxic than their parent compound in a cytotoxicity assay performed 
on L929 murine cells (Eljezi et al. 2017), and treatment with DINCH in a Sertoli cell line 
resulted in numerous gene expression changes, including genes involved in the major 
cancer signal transduction ERK/MAPK pathways (Nardelli et al. 2015). One 
epidemiologic study found negative associations between urinary OH-MINCH 
concentrations and peak estradiol levels and number of total oocyte yields among women 
undergoing in vitro fertilization treatments (Mínguez-Alarcón et al. 2016). Therefore, 
additional toxicological and epidemiological studies on this plasticizer and its metabolites 
are needed to determine its safety for human exposure. 
4.5 Conclusions 
Here we report results from only the second biomonitoring assessment of urinary 
DINCH metabolite concentrations in the U.S., as well as the first results from a test of 
DINCH metabolites on ESR1 and PGRB transactivation assays. In summary, we found 
urinary DINCH metabolites in relatively low concentrations in this population of 
pregnant women. Similar to other biomonitoring studies, OH-MINCH was the most 
prevalent metabolite. African American women had significantly higher DINCH and 
phthalate metabolite concentrations than Caucasian women, suggesting the two 
plasticizers share common exposure pathways. We found that DINCH metabolite 
concentrations did not change from 2011 to 2014, which is discordant with previous 
results showing increasing exposures. Urinary DINCH metabolite concentrations did not 
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increase when sampled at time of delivery compared to the second trimester, suggesting 
that DINCH is not used in medical devices at MUSC. Finally, DINCH metabolites did 
not induce estrogenic or progestogenic activity. Body burdens of this phthalate 
replacement are likely to further increase. It is important to continue to monitor human 
exposure, especially in vulnerable populations, and to perform rigorous testing to ensure 




Table 4.1. HPLC gradient program for DINCH metabolites. Flow rate: 0.25 mL/min; 
mobile phase A: 0.1% (volume fraction) acetic acid in deionized water; mobile phase B: 
0.1% (volume fraction) acetic acid in acetonitrile. 
 
Time (minutes) % A % B 
0 75 25 
10 55 45 
15 50 50 
20 45 55 
25 35 65 
30 0 100 
40 0 100 
40.5 75 25 





Table 4.2. Optimized source and gas parameters for DINCH metabolites. CUR, curtain 
gas pressure; IS, ion spray voltage; TEM, temperature; GS1, gas 1 (nebulizer gas); GS2, 
gas 2 (heater gas); Ihe, interface heater; CAD, collision activated dissociation gas. 
 
MS Parameters Optimized Value 
CUR 45 psig 
IS -4500 V 









Table 4.3. DINCH metabolites and their native and labeled precursor and product ion 
transitions, and optimized compound parameters. Quant, quantifier ion; qual, qualifier 
ion; DP, declustering potential (V); CE, collision energy (V); CXP, collision exit 
potential (V); EP, entrance potential (V). 
 
DINCH metabolite Precursor/Product Ions (m/z) DP CE CXP EP 
OH-MINCH (quant) 313/153 -90 -35 -13 -10 
OH-MINCH (qual) 313/109 -90 -35 -13 -10 
OH-MINCH-d4 317/153 -90 -35 -13 -10 
cx-MINCH (quant) 327/173 -90 -40 -15 -10 
cx-MINCH (qual) 327/153 -90 -40 -15 -10 
cx-MINCH-d2 329/175 -90 -40 -13 -10 
oxo-MINCH (quant) 311/153 -90 -35 -13 -10 





Table 4.4. Limits of detection, detection frequency, range, and median concentrations of 
urinary DINCH metabolites (ng/mL) overall and by race during the second trimester of 
pregnancy between 2011 and 2014. LOD, limit of detection; DF, detection frequency   
a Specific gravity-adjusted vales are in italics beneath unadjusted values; * p = 0.003 
using Mann-Whitney U Test for differences by race; ** p = 0.01 using Mann-Whitney U 
Test for differences by race. 
 






(%) Range a 
Overall  
(n = 100) 
African 
American 
(n = 50) 
Caucasian 
(n = 50) 
OH-MINCH 0.04 98 <LOD – 1.58 0.18  0.20 * 0.12  
   <LOD – 2.79 0.20 0.23 ** 0.13 
oxo-MINCH 0.10 44 <LOD – 1.01 - - - 
   <LOD – 1.06    
cx-MINCH 1.0 1 <LOD – 1.30 - - - 





Table 4.5. Distribution of urinary OH-MINCH concentrations by year (ng/mL) a.  
SD, standard deviation; a SG-adjusted values are in italics beneath unadjusted values, b 
No differences according to Kruskal-Wallis Test (p = 0.86 for unadjusted; p = 0.67 for 
SG-adjusted). 
 
Year Mean (SD) Median b Range N 
2011 0.25 (0.31) 0.18 <LOD – 1.58 24 
 0.33 (0.31) 0.23 <LOD – 1.27  
2012 0.30 (0.33) 0.19 <LOD – 1.44 24 
 0.42 (0.48) 0.22 <LOD – 2.01  
2013 0.21 (0.18) 0.18 <LOD – 0.72 25 
 0.26 (0.26) 0.20 <LOD – 0.95  
2014 0.30 (0.33) 0.17 <LOD – 1.39 27 




















Figure 4.1. DINCH is manufactured by catalytic hydrogenation of the aromatic ring of 



































Figure 4.4. Diagram of transactivation assay dosing strategy on a 96-well plate. 
Concentrations are in M; Top numbers represent well number and letters on left represent 
well rows. 
  









Natural Ligand (10-9 E2/10-7 P4) 10-8 OH MINCH 10-5 CX MINCH 10-7 MEHP
Natural Ligand (10-8 E2/10-6 P4) 10-7 OH MINCH 10-9 OXO MINCH 10^-7 mixture
Natural Ligand (10-11 E2/10-9 P4) 10-5  MINCH 10-7 CX MINCH 10-9 MEHP
Natural Ligand (10-10 E2/10-8 P4) 10-9 OH MINCH 10-6 CX MINCH 10-8 MEHP
Natural Ligand (10-13 E2/10-11 P4) 10-7  MINCH 10-9 CX MINCH 10-6 OXO MINCH
Natural Ligand (10-12 E2/10-10 P4) 10-6  MINCH 10-8 CX MINCH 10-5 OXO MINCH
DMSO 10-9 MINCH 10-6 OH MINCH 10-8 OXO MINCH







Figure 4.5. Spearman’s correlation analysis of SG-adjusted urinary concentrations of OH-





Figure 4.6. Median urinary OH-MINCH concentrations (ng/mL) vary by race a.  
a p = 0.01 using Mann-Whitney U Test for SG-adjusted differences by race; Box = 25th 
and 75th percentiles of SG-adjusted urinary OH-MINCH concentrations; bars = min and 





Figure 4.7. Urinary OH-MINCH concentrations do not vary by year a.  
a p = 0.67 using Mann-Whitney U Test for SG-adjusted differences by year; Box = 25th 
and 75th percentiles of SG-adjusted urinary OH-MINCH concentrations; bars = min and 





Figure 4.8. Concentrations of OH-MINCH are lower at delivery than during the 2nd 
trimester in seven out of eight paired samples. Concentrations are higher at delivery than 
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Figure 4.9. ESR1 (ERα) transactivation by DINCH metabolites and MEHP. Test 
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Figure 4.10. PGRB transactivation by DINCH metabolites and MEHP. Test chemicals 





Figure 4.11. Some phthalate metabolites increase at delivery a. T1 = 18 to 22 weeks of 
gestation; T2 = 24 to 32 weeks of gestation; a Concentrations are SG-adjusted median ± 
95% confidence intervals; * p < 0.0005 for a Friedman’s two-way ANOVA by ranks; n = 



































Chapter 5. Summary, Future Directions, and Conclusions 
5.1 Summary and Future Directions 
The research established for this dissertation originated from a larger study aimed 
to determine if prenatal phthalate exposure resulted in measureable in utero biomarkers 
of endocrine disruption. While the questions addressed herein were initially ancillary to 
the main research project, we have generated valuable information that will contribute to 
the advancement of this field.  
We first sought to determine if urinary phthalate metabolite concentrations in our 
population of pregnant women were consistent with concentrations reported nationally. 
Second, we questioned if there were any unique sociodemographic variables that were 
associated with higher or lower phthalate concentrations. Reports from the Centers for 
Disease Control and Prevention’s (CDC) National Health and Nutrition Examination 
Survey (NHANES) provide a broad overview of phthalate metabolite concentrations in 
the U.S. population by gender, age group, and race; however, Charleston, South Carolina 
is a unique area, specifically with regard to cultural diversity and dietary habits, 
providing reason to suspect distinctive patterns of phthalate exposure locally. After 
performing univariate analyses on an extensive list of independent sociodemographic 
variables, we ultimately decided to focus our efforts on uncovering associations between 
phthalate concentrations and age, BMI, race, education, marital status, and education.  
We found that African American women had higher concentrations of every 
phthalate metabolite than Caucasian women, and that difference was significant for six of 
the eight metabolites. We performed a pilot study to determine if phthalate metabolism 
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contributed to the racial differences in phthalate concentrations by examining phthalate 
glucuronidation patterns by race. Measuring the ratio of free phthalates (not bound to 
glucuronide) to total phthalates (free and glucuronide-bound phthalates) provides an idea 
of how phthalates are metabolized. We found that phthalate glucuronidation patterns 
were not different between races, except for MEHHP (Figure 5.1). Therefore, it is likely 
that racial differences in phthalate concentrations are not the result of differential 
phthalate metabolism alone, rather, African American women are exposed to more 
phthalates than Caucasian women. 
After controlling for all other variables, race was significantly associated with 
four phthalate metabolites, and BMI and education were associated with three 
metabolites. Women who were African American, heavier, and/or less educated 
consistently had higher phthalate concentrations. However, African American women in 
our population were more likely to be heavier and less educated than Caucasian women. 
In an effort to clarify these relationships within each race, we also performed the analysis 
stratified by race. We found that age, BMI, education, and income were significantly 
associated with phthalate concentrations in African American women, while marital 
status was significantly associated with phthalate concentrations in Caucasian women.  
For African American women, education was the most influential predictor of 
phthalate concentration. College-educated African American women had significantly 
lower phthalate concentrations than less-educated women, implying that African 
American women with a college education are exposed to fewer phthalates, presumably 
through less consumption of processed or packaged food and less use of phthalate-
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containing personal care products. There was no association between marital status and 
phthalate concentrations in African American women, but only 25% of African American 
women in our study were married. Thus, educational attainment, rather than marital 
status, influenced lifestyle choices associated with phthalate exposure in African 
American women.  
We were surprised to find that marital status was the only significant predictor of 
phthalate concentration in Caucasian women. We were also surprised that monoethyl 
phthalate (MEP) was not one of the four phthalate metabolites significantly associated 
with marital status in Caucasian women, as we would expect it to be higher in unmarried 
women because it is commonly found in personal care products and cosmetics. Due to 
trade secrets, phthalates do not have to be listed as ingredients in personal care products; 
therefore, it is possible that uncertainty exists over phthalate use in personal care products 
or that MEP does not represent personal care product exposure in our population. Still, 
our results suggest that single Caucasian women are exposed to more phthalates than 
married Caucasian women. It is likely that lifestyle differences between married and 
unmarried women contribute to the variations in phthalate concentrations. We 
hypothesize that unmarried Caucasian women use more personal care products and 
cosmetics, and consume more processed food and beverages than married Caucasian 
women. To our knowledge, this was the first study to detect an association between 
marital status and phthalate concentrations. 
We were unable to directly identify sources of phthalate exposure with the data 
collected thus far. Minimally, detailed dietary journals and types, amounts, and 
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frequencies of personal care products used would also be needed to estimate sources of 
phthalate exposure. Basic dietary habit information was collected in the study 
questionnaires, including how often participants consumed process foods, drank from 
plastic water bottles, and reheated food in plastic storage containers. In the future, this 
information could be used to identify potential dietary sources of phthalate exposure.  
With the acknowledgment of factors contributing to high phthalate concentrations 
comes an opportunity to reduce exposure. Results from this study should be used to 
inform an educational intervention program aimed at reducing phthalate concentrations in 
pregnant women, especially pregnant women shown to be at risk for high exposure. 
Phthalate exposure, while unavoidable, can be reduced with behavioral modifications. 
Therefore, future efforts should focus on educating men and women about potential 
sources of phthalate exposure and exposure reduction strategies. 
In Chapter 3, we sought to determine if maternal urinary phthalate concentrations 
were associated with abnormal reproductive development in newborns. Since phthalates 
are known antiandrogens, we used anogenital distance (AGD, a biomarker of in utero 
androgen exposure) as the reproductive development endpoint. This was the first study to 
analyze the impact of race on the relationship between prenatal phthalate concentrations 
and AGD outcomes. We identified consistent inverse associations between phthalates and 
APD among boys and a longer ASD with higher MBP, MBzP, ∑DBP, and ∑BzBP, 
without evidence for interaction by race. Among girls, we found no association for AFD, 
but detected race-based interactions, in which ACD was longer for whites and shorter for 
non-whites, following exposure to MBP, MEP, ∑DBP, and ∑BzBP.  
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Our results are similar to previous human studies showing inverse associations 
between prenatal phthalate exposure and APD in boys; however, our finding of a positive 
relationship between phthalates and ASD is quite unexpected. Following phthalate 
exposure, the current hypothesis is that the resulting antiandrogenic activity would lead to 
a reduction of both the APD and ASD. Our results suggest that the development of the 
AGD and ASD are unique physiological events that may be influenced differently by 
prenatal phthalate exposure. ASD is a smaller distance than AGD, potentially making 
measurement more difficult, but measurement error is unlikely as measurements were 
taken three times and averaged with low variability. Additionally, ASD historically 
shows good between-measurer agreement and is least affected by age of the infant (Dean 
et al. 2013). In the future, researchers should collect an additional measure of scrotal 
development, such as scrotal volume, in order to clarify these issues. It is interesting and 
worth noting that DEHP metabolites exerted the expected antiandrogenic effects on both 
APD and ASD, demonstrating that effects of DEHP are consistently antiandrogenic 
across several human studies.  
In females, we did not anticipate finding any significant associations between 
phthalate exposure and anogenital distance, and we were unsure of how race would 
impact these relationships if they were found. Perhaps the most unexpected finding was 
that ACD in Caucasians increased while ACD in African Americans decreased, but AFD 
was not impacted following phthalate exposure. Inconclusive results in this study and 
others suggest that more research is needed to understand the effects of phthalate 
exposure on newborn girls. A recent study found that newborn daughters of women with 
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PCOS (Polycystic vary syndrome; hypothesized to be related to an excess of androgens) 
had longer ACD and AFD than daughters of women without PCOS (Barrett et al. 2016). 
Connecting these results to our own, one might hypothesize that phthalates exert an 
androgenic effect on ACD in Caucasians and an antiandrogenic effect on ACD in African 
Americans. However, such hypotheses would be premature, given our modest sample 
size of 61 Caucasian girls and 67 African American girls. Ultimately, we still do not 
know why ACD increases in Caucasians and decreases in African Americans, or why 
there are no changes in AFD following phthalate exposure. A larger future investigation 
should clarify the biological mechanisms involved in these processes, and 
epidemiological studies should include female infants in addition to males.  
In addition to genital measurements, data on birth outcomes (including 
birthweight, gestational age, and preterm birth), preeclampsia, and genitourinary 
anomalies (including hypospadias, undescended testis, penile hydrocele, penile torsion, 
penile chordae, and labial tag) were also collected at delivery. We are collaborating with 
epidemiologists to evaluate associations between phthalate concentrations and these birth 
outcomes. Only 1 mL of urine was used for phthalate analyses, so extra samples have 
been frozen for future studies. This comprehensive data set from a unique and racially 
diverse population is extremely valuable and will continue to be used to explore 
associations between gestational exposures and birth outcomes in the future.   
The main limitation to this study and dissertation as a whole is that urine was not 
collected in the first trimester of pregnancy. The first trimester is arguably the most 
important time for reproductive organ development in a fetus. Here, all analyses were 
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performed with phthalate analyses from urine collected between 18 and 22 weeks’ 
gestation. It would be valuable to repeat the analyses with first trimester urine samples, as 
the results might clarify remaining questions and inconsistencies between our study and 
others. We could repeat all analyses for Chapters 2 and 3 with urine samples collected 
between 24 and 32 weeks of gestation, but we have fewer samples from this time point, 
weakening the statistical power. Additionally, the makeup of the population supplying a 
second urine sample varies greatly from the initial population described in Chapter 2, and 
we would not expect exposures from later stages of gestation to influence development as 
much as exposures from the first or early second trimesters. The use of a single spot urine 
sample was another limitation of this study; however, it was not feasible to collect more 
than one urine sample within 24 hours per person for a study population of this size, 
considering supplies, freezer space, and research coordinators, and research technicians 
were limited. 
In Chapter 4, we reported concentrations of a phthalate alternative, DINCH, for 
only the second U.S. population ever to be assessed for such exposures. Urinary 
concentrations of DINCH metabolites ranged from 0.13 ng/mL to 0.23 ng/mL and were 
higher in African American than in Caucasian women. Concentrations remained 
consistent from 2011 to 2014 and did not increase at delivery like some phthalate 
metabolites did. When tested on transactivation assays, DINCH metabolites alone and in 
a mixture did not elicit an estrogenic or progestogenic response.  
Since these chemicals were introduced in 2002, and were not regularly detected in 
human samples until 2007, we were unsure if they would be detectable in our population. 
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There is a great deal of uncertainty regarding the commercial use of these chemicals. We 
did not know if only more progressive “green” companies had decided to move away 
from phthalate formulations in favor of DINCH, or if phthalate replacement was 
widespread and occurring across commercial industries. DINCH metabolite 
concentrations in our population were much lower than phthalate metabolite 
concentrations, indicating that phthalate replacement by DINCH is not yet widespread. 
However, 98% of our population had detectable urinary concentrations of at least one 
DINCH metabolite, suggesting that nearly everyone is exposed to low levels of DINCH 
regularly. Because we see the same racial pattern of DINCH exposure as phthalates, with 
higher concentrations in African American women than in Caucasian women, we suspect 
that phthalate replacement by DINCH is universal across the plastics industry versus 
being used in a niche “green” market. 
We were surprised that urinary DINCH concentrations did not increase from 2011 
to 2014 in our study, as nearly every other study has found increasing concentrations over 
time. Future research should continue to monitor the prevalence of these compounds, as it 
might take longer for phthalate alternatives to expand to suburban and rural areas. Here, 
we have evidence that pregnant women were exposed to DINCH as early as 2011, but 
DINCH concentrations have remained consistent locally through 2014.  
It is important to rule out all hormone receptors as potential targets of DINCH 
endocrine disruption. We found that DINCH metabolites did not exhibit estrogenic or 
progestogenic activity, but it is still possible (and even likely, considering their similar 
structures) that DINCH metabolites could act as antiandrogens or bind the peroxisome 
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proliferator-activated receptors similarly to phthalates. It would be ideal to find that 
DINCH is a safe phthalate alternative, but we should remain cautiously optimistic until 
thorough screening has been completed. Endocrine disruptor screening programs exist, 
however, the process can take years to approve or disprove one compound. The burden 
lies on scientists and consumers to challenge the efficacy of chemicals used in every day 
products. Regular biomonitoring efforts are essential for identifying potential new threats 
to human health.  
 
5.2 Conclusions 
The research in this dissertation has demonstrated that race is the most important 
predictor of phthalate concentration in local pregnant women, establishing racial 
disparities of phthalate exposure that are likely contribute to health disparities. At a time 
when multiple studies have consistently found that phthalate concentrations are inversely 
related to AGD in newborn boys, our study has revealed that race may play a larger role 
in the relationship between endocrine disruption and reproductive development than we 
suspected. Future studies should integrate race and other non-chemical modulators of 
endocrine disruption into research objectives. We also found that local pregnant women 
were commonly exposed to a novel phthalate replacement chemical, DINCH, at 
consistently low concentrations. Results from our transactivation assays are in support of 
initial toxicology reports suggesting DINCH is a safe phthalate replacement; however, 
additional testing is needed. 
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 Endocrine disrupting compounds, including phthalates, represent a global threat 
to reproductive health and disease. While phthalates are common in plastics and personal 
care products, these products are likely to contain many other endocrine disruptors, such 
as flame retardants, parabens, bisphenols, preservatives, formaldehyde, triclosan, and 
pigments. Exposure to EDCs in the U.S. is estimated to cost $340 billion as a result of 
diseases such as diabetes, obesity, endometriosis, infertility, neurological effects, and 
cardiovascular deaths from reduced testosterone (Attina et al. 2016, Trasande et al. 
2016). Environmental exposures arising from modern lifestyle have infiltrated our bodies 
and influence reproductive development. There is an urgent need to monitor and reduce 
exposures to ensure proper reproductive development and to prevent the onset of disease 





Figure 5.1: A Mann-Whitney U test was used to determine if percent of free phthalates 
varied for each analyte between African American and Caucasian women. % Free values 
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